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1. Introduction 
Almost four decades ago, Porter (Porter, 1970) and Edelman (Edelman, 1970) established the 
structure of antibodies (immunoglobulins). This discovery dramatically improved the 
understanding that antibodies function as both receptor and effector molecules. Humoral or 
antibody-mediated immunity requires noncovalent contact between antigens (ligands) and 
antibodies (receptors). Hypervariable regions of immunoglobulin light and heavy chains 1, 
2, and 3, which are termed complementarity-determining regions (CDR), are primarily 
involved in the interaction with antigens (Figure 1).  
 
 
Fig. 1. Three-dimensional structure of HLA-I and alloantibody IgG complex. 
1. HLA class I protein 
2. IgG molecule.  
    a. Variable regions of light and heavy chains 
    b. Constant region of heavy chains 
3. CDRs 1, 2, and 3 of heavy and light chains 
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The contact region of the antigen that the antibody binds to is called the epitope, or 
antigenic determinant. The portion of antibody that makes this contact is referred to as the 
paratope. Antibody effector functions are specified by the constant domains of heavy chains. 
Their most important function is the activation of the complement cascade, which is 
triggered by conformational changes in the hinge area after antigen binding. Complement 
activation results in the destruction of the cell membrane. An additional important effector 
function of immunoglobulins is their binding to pathogens, including bacteria and viruses. 
Pathogens that are coated with antibodies are recognized by Fc (constant fragment) 
receptors that are expressed on the surfaces of reticuloendothelial cells, including 
macrophages, monocytes, neutrophils, and dendritic cells. This event not only results in the 
elimination of the pathogen from the circulation and the tissues but also triggers additional 
functions of these cells, such as phagocytosis and degranulation. The latter ultimately results 
in the destruction of the invading pathogen. In contrast to strong and irreversible covalent 
bonds, antibody-antigen interactions are noncovalent. They strictly depend on temperature, 
pH, ionic strength, van der Waal’s forces, hydrogen bonds and hydrophobic interactions. 
These weak bonds are formed by the interactions of many groups of biological molecules, 
including IgG, nominal protein antigens, and major histocompatibility complex (MHC) class 
I and class II proteins. In humans, the latter are called human leukocyte antigens (HLAs). A 
unique characteristic of genes that code HLAs is the extremely high occurrence of 
polymorphisms.       
2. Role of alloantibodies in kidney transplantation 
In kidney transplantation, graft outcomes critically depend on the degree of HLA matching 
between the donor and recipient (Abe et al., 1997; Akalin & Pascual, 2006; Balan et al., 2008; 
Bas et al., 1998; Claas et al., 2005; Scornik et al., 1992; Takemoto et al., 2004; Terasaki 2003; 
Terasaki & Cai, 2005, 2008;). Although the cellular component of the allogenic immune 
response to the transplanted tissue plays a key role in this matching, the contribution of 
antibodies should not be underestimated (Arnold et al., 2005; Bartel et al., 2007; Stegall et al., 
2009; Sumitran-Holgersson, 2001; Vasilescu et al., 2004; Zeevi et al., 2009). Transplant 
candidates (TCs) with preexisting antibodies against HLA are called sensitized patients. The 
percent of reactive antibodies (PRA) is a major characteristic that defines the level of 
sensitization. Essentially, greater PRA values indicate greater numbers of anti-HLA 
antibodies in the patient, indicating a lower probability of receiving a kidney transplant. 
Indeed, donor-specific antibodies (DSAs) undeniably participate in hyperacute rejection 
(HAR), humoral acute rejection [also called accelerated antibody-mediated rejection (AMR)], 
and chronic rejection (CR) (Claas & Doxiadis, 2009; Gebel et al., 2003; Georgescu et al., 2007; 
Grandtnerova et al., 2008; Kerman et al., 1997; Lefaucheur et al., 2009; Poli et al., 2009; 
Scornik et al., 1989, 1992; Supon et al., 2001; Takemoto, 1995; Terasaki & Cai, 2008; Vasilescu 
et al., 2004; Ferry et al., 1997; Martin et al., 2003). HAR is frequently caused by preexisting 
DSAs that are directed at mismatched HLAs or by high concentrations of isohemagglutinins 
against major blood group antigens. Graft loss due to HAR has been shown to take place 
within hours after transplantation; however, in particular cases, wherein the recipient is 
exposed to multiple cycles of plasmapheresis (PP), post-transplant HAR may develop days 
later, and this condition is termed delayed HAR (DHAR). The pathological findings in both 
scenarios appear to be the same (Sugiyama, 2005). Today, HAR is a rare event owing to 
development of highly sensitive flow cytometry (FC) cross match (CM) technology, which 
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enables the prospective detection of low concentrations of DSAs (Bray, 1994; Shenton et al., 
1995; Wang-Rodriguez & Rearden, 1995). Relatively low concentrations of preexisting DSAs 
are generally not a contraindication for transplantation (Bray, 1994, 2001; Gebel & Bray, 
2000; Graff et al., 2009; Reinsmoen et al., 2008).       
2.1 The development of alloantibodies against HLAs  
In more than 30% of transplant cases, DSAs develop post-transplant, increasing the risk of 
AMR (Christiaans et al., 1998; Haririan et al., 2009; Martin et al., 2003; McKenna et al., 2000; 
Zachary et al., 2005). The development of these antibodies depends on multiple factors, 
including the immunogenicity of mismatched HLAs, HLA class II typing of the responder, 
immunosuppressive protocols, cytokine and chemokine production, and the hormonal 
background of the recipient (Adeyi et al., 2005; Claas et al., 2005; Fuller et al., 1999; Fuller & 
Fuller, 1999; Lachmann et al., 2008; Laux et al., 2003; Lobashevsky et al., 2002). Regulatory 
immune cells, such as NKT cells, T regs (CD4+/CD25+) (Tsang et al., 2007; Stasi et al., 2008 ; 
Bas et al., 1998; Jiang & Lechler, 2003; Levings & Thomson, 2009; Toyofuku et al., 2006) and 
B regs (so-called CD1d/CD5 B10 cells) (Amu et al., 2007), substantially contribute to the 
development of antibody-mediated immunity. Anti-HLA antibodies have been 
demonstrated in patients with a history of blood transfusion(s), pregnancy and previous 
transplant(s). In addition, serological cross-reactivity between HLA-B27 and the 60.0-80.0 kD 
protein of Klebsiella pneumoniae has been demonstrated (Husby et al., 1989; Ogasawara et al., 
1986). Considerable effects on antibody profiles of pre-sensitized TCs may also be produced 
by vaccinations, including Hepatitis B/C and influenza. Indeed, Danziger-Isakov and R. 
Kennedy have reported bystander effects of vaccine immunization on humoral alloreactivity 
(Danziger-Isakov et al., 2010; Kennedy et al., 2010). The mechanism of vaccination-mediated 
sensitization in TCs has been described as follows. Antigen-specific CD4+ T helper cells are 
central components in naturally acquired and vaccine-induced immunity. These cells 
control the differentiation of HLA-specific B cells into plasma (antibody producing) cells 
and memory cells through the production of cytokines, such as interleukin (IL)-4, IL-5, IL-6, 
IL-2, IL-13, and IFN. Subsequent vaccination or infection triggers distinct groups of T 
helper cells to begin producing the cytokines mentioned above. These cytokines activate 
quiescent B memory and long-living plasma cells that reside in the bone marrow. These 
HLA-specific plasma cells then begin vigorously producing antibodies, resulting in changes 
in the PRA (Benson et al., 2009; Di Genova et al., 2010; Di Genova et al., 2006). Recently, the 
development of so-called “natural” anti-HLA antibodies has been reported by P. Terasaki’s 
group. These investigators discovered that natural immunizing events, such as infection, 
protein ingestion and allergen exposure, result in the formation of HLA-A, - B, -C, and DQ 
loci-specific alloantibodies in non-alloimmunized healthy males. The “natural” antibodies 
are directed against rare HLA specificities, such as A80, B76, A82, and C17, and should not 
be ignored in clinical decisions for organ allocation (Morales-Buenrostro et al., 2008). 
2.2 B lymphocytes and alloantibody production  
After naïve CD20+/CD138-/CD38-/CD27- B cells interact with the HLA protein antigen, 
two key events occur. First, the naïve B cells become activated in lymphoid tissue, 
differentiate into short-lived CD20-/CD138-/CD38+/CD27- plasma cells (PCs), and  
secrete low-affinity antibodies. Second, another group of activated B cells rapidly  
divides and differentiates into long-term, high-affinity antibody-secreting CD20-
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/CD138+/CD38+/CD27- PCs upon interaction with follicular dendritic cells after receiving 
signals, such as IL-4 and IL-5, that are produced by T helper cells (Stegall et al., 2009; 
Higgins et al., 2009). These cells often migrate back to the bone marrow, where they may 
continuously secrete antibodies for years. An additional important event in the process of 
alloantibody production is the formation of B memory CD20+/CD27+ CD138-/CD38- cells, 
which are able to transform into long-lived PCs after secondary stimulation by antigens or 
bystander T cells (Stegall et al., 2009; Bohmig et al., 2008; Cai & Terasaki, 2005; Armitage & 
Alderson, 1995) (Figure 2). 
 
 
Fig. 2. Model for the generation of long-lived alloantibody-secreting plasma cells (PC) after 
recognition of HLA. APC, antigen presenting cells; LN, lymph node; GC, germinal center; 
3. Some immunological factors determining alloantibody production 
As mentioned above, the risk of AMR and kidney graft survival strictly depends on HLA 
matching between donor and recipient tissues. Highly sensitized TCs, i.e., those having a 
high PRA, have the highest risk of AMR-mediated graft failure. In addition, these patients 
are disadvantaged in comparison to those with a low PRA. They typically experience longer 
times on the waiting list (until a cross-match-negative donor is found) and dialysis. 
Numerous clinical studies since the 1990s have demonstrated various strategies for 
identifying donors for high PRA patients. Rodey’s and Takemoto’s groups have reported 
successful kidney graft outcomes and negative cross-matching when HLA matching was 
performed using cross-reactive groups (CREG) and/or public epitopes (Rodey & Fuller, 
1987; Takemoto, 1995, 2004). Terasaki’s method for analyzing donor and recipient 
compatibility applies the amino acid sequencing of HLA alleles (Cai et al., 2006; Deng, 2008; 
El-Awar et al., 2005, 2006a, 2006b, 2007; El-Awar & Terasaki,  2007).  
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3.1 Amino acids and the triplet/eplet concept of HLA matching 
In 2002, Duquesnoy described a molecularly-based algorithm for histocompatibility 
determination called HLAMatchmaker (Duquesnoy, 2002). This approach considers a 
comparison of linear amino acid residue (AAR) sequences (or triplets) between donors and 
recipients to be elements of potential epitopes. Therefore, each HLA protein represents a 
linear sequence of triplets, and the degree of mismatch is assessed by the number of triplets 
that are not shared between the donor and recipient. There are two important points in this 
approach. First, the location of the particular triplet in the HLA protein is carefully 
examined. Only those AARs that are accessible to antibodies, i.e., triplets residing on ǂ-
helical coils and ǃ-loops, are considered. In contrast, those triplets that are located on the ǃ -
pleated floor and beneath the ǂ-chains are not available for antibody binding (Figure 3).  
 
 
Fig. 3. Three-dimensional structure of HLA-I molecule (top view). 
1. ǂ helical coils 
2. oligopeptide located in the antigen presenting groove 
3. ǃ loops 
4. ǃ pleated floor of antigen presenting groove 
For this reason, the mismatched triplets residing on the bottom of the antigen-presenting 
groove of the HLA proteins are often not critical to antibody production and are not 
immunogenic. Secondly, alloantibodies can be produced only against non-self mismatched 
triplets. Subsequent clinical studies have proven the validity of the HLAMatchmaker 
algorithm as a method for finding cross-match compatible donors for TCs with PRA values 
above 80% (Claas et al. 2005; Claas et al. 2004; 2005; Doxiadis et al. 2005; Duquesnoy 2007, 
2008a, 2008b; Duquesnoy & Claas, 2005; Lobashevsky et al., 2002). Furthermore, AAR triplet 
analysis has appeared to be capable of explaining or predicting the development of non-DSAs 
in kidney allograft  recipients (Lobashevsky et al., 2002; Adeyi et al., 2005); however, 
subsequent clinical studies of alloantibody profiles in post-transplant nephrectomized TCs 
have demonstrated that the HLAMatchmaker computer algorithm provides an incomplete 
HLA epitope repertoire. Indeed, an inconsistency between mismatched triplets and the pattern 
of antibody reactivity has been reported. In 2005, Duquesnoy’s group, using human 
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monoclonal antibodies, demonstrated reactivity against HLA-A3 (triplotype 62Qe, 142mI, 
144tKr, and 163dT) owing to a unique 163dT triplet; however, other monoclonal antibodies 
also reacted with 62Qe, 142mI, or 144tKr triplets, although these triplets were present on 
different HLA-A locus antigens. Furthermore, the 62Qe triplet that is carried by A30 and A31; 
the 142mI triplet that is carried by A23, A24, A25, and A32; and the 144tKr triplet that is 
carried by A80 did not react with the monoclonal antibodies that were directed against the 
triplets mentioned above (Duquesnoy et al., 2005). Similar results were summarized in a report 
on the structural basis of HLA compatibility at the 14th International HLA and 
Immunogenetics Workshop (Duquesnoy & Claas, 2007). Further investigations of the three-
dimensional structure of antibody-antigen complexes showed that functional HLA epitopes 
could be presented by a group of AARs that are not located beside one another, but rather 
represent a 3-Å to 5-Å radius patch. These patches have been defined as “eplets.” Some of 
eplets include short sequences of AARs, which are equivalent to triplets, whereas, others 
contain residues that are located distally (apart). For instance, the presence of glycine in 
position 56 is required for reactivity of monoclonal antibodies specific for 62Qe triplet. The 
AARs of each eplet are clustered together on the surface of the HLA protein molecule that 
represents a functional immunogenic epitope (Marrari et al., 2010; Marrari & Duquesnoy, 2010; 
Duquesnoy et al., 2005; Duquesnoy & Askar, 2007) (Figure 4). Therefore, the eplet concept of 
the HLAMatchmaker algorithm appears to more accurately define functional HLA-A, -B, -C, -
DR, -DQ (andchains) and DP (andchains) epitopes (Claas et al., 2005; Claas & 
Duquesnoy, 2008; Duquesnoy, and Marrari, 2010; Duquesnoy, 2006, 2008a, 2008b; Duquesnoy 
& Askar, 2007; Marrari et al., 2010; Lomago et al., 2010). Thus, HLA epitope- (eplet) matching 
using the HLAMatchmaker computer algorithm represents a robust and valid approach to 
finding compatible donors for highly sensitized TCs. It may also be used to analyze antibody 
reactivity patterns in sensitized patients by defining the mismatched eplets the patient has 
been exposed to. This information, in turn, facilitates the interpretation of antibody profiles in 
TCs. In addition, a comparative analysis of the HLA epitopes that were defined by Terasaki’s 
group (amino acids that are unique to a group of alleles that react with mouse monoclonal 
antibodies) and HLA epitopes that are defined by eplets showed more than a 90% correlation 
(Marrari & Duquesnoy, 2010; Duquesnoy & Marrari, 2010). 
 
 
Fig. 4. Topography of 62Q eplet (red circle) of HLA-A*03:01 allele consisting of two patches 
(blue circles) 56G and 62, 63, 65, 66QERN. These patches are approximately 11Ǻ apart 
(yellow arrow). 
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3.2 HLA class II typing of the responder 
It is generally accepted that mismatched allogenic HLAs can be recognized by the immune 
system both directly and indirectly. In kidney transplantation, both of these processes take 
place simultaneously. The immunological response to non-self HLAs is MHC restricted. The 
phenomenon of MHC restriction postulates that non-self proteins, including HLAs, are 
recognized by the immune system after being processed and presented by host antigen 
presenting cells, in the context of self-MHC I and/or MHC II, to the responder’s (host) T 
cells (Doherty and Zinkernagel, 2005). Although many factors influence the strength of the 
immune response, the affinity between the members of the tri-molecular complex, including 
self-HLA II, peptide, and T cell receptors (TCRs), is believed to be the most important. HLA 
class II proteins have six regions or pockets that participate in peptide binding. These 
pockets contain highly polymorphic amino acids, which interact with the motifs of the 
peptides that are being presented to the TCRs. The stronger the affinity between the peptide, 
HLA and TCRs, the stronger the stimulation signal the T cell receives. Anderson and 
colleagues have demonstrated that antibody production against tumor HEP-2 peptide was 
considerably stronger in an HLA-DR11 patient than in an HLA-DR14 individual (Anderson 
et al., 2000). Furthermore, a report by Fuller demonstrated increased antibody synthesis 
against HLA-Bw4 antigenic inclusions in HLA-DRB1*01 or HLA-DRB1*03 positive 
individuals in comparison to HLA-DRB1*04 recipients (Fuller & Fuller, 1999).  
4. Role of alloantibodies directed against other than HLA determinants  
4.1 Antibodies against A and B blood groups 
The compatibility of HLA and the ABO blood groups, which are two antigenic systems in 
the human body, have a significant effect on graft outcome. Historically, ABO 
incompatibility has been considered to be an absolute contraindication for renal 
transplantation due to the high risk of HAR development that is caused by preexisting anti-
A or anti-B antibodies. Unlike HLA, the A, B and O (H) blood group antigens are 
oligosaccharides that structurally differ via ǂ-galactose (ǂ-Gal) and N-acetyllactosamine 
(NAc). Adding these sugars to precursor backbones requires catalyzation by a group of 
enzymes that are called glycosyltransferases. The A blood group has two common 
subgroups, A1 and A2. There are quantitative and qualitative differences between A1 and 
A2; the A1 phenotype has 4 glycolipids, whereas the A2 phenotype contains very low levels 
or none at all. Immunological cross-reactivity between them has been reported (Gloor et al., 
2006; Gloor & Stegall, 2007; Tyden et al., 2010). Furthermore, 8% of A2 individuals produce 
antibodies against A1. The ABO system also plays an important role in kidney allocation; 
donors and recipients must be either ABO identical or compatible (Futagawa & Terasaki, 
2006). A/B antigens are known to be passively absorbed by different tissues of the kidney, 
including the glomerular endothelium and the tubular epithelium (Rivera & Scornik, 1986, 
Aikawa et al., 2003; Fidler et al., 2004; Rydberg et al., 2007). Endothelial and epithelial cell 
surface densities of A/B antigens are also different. For example, the A blood group antigen 
has higher expression levels than the B blood group antigen. Interestingly, 
immunohistochemical analysis has revealed that the A2 blood group has the lowest cell 
surface expression (Pober et al., 1997; Shimmura et al., 2004; Yung et al., 2007); however, 
data analysis of kidney transplants that has been performed across ABO barriers has not 
revealed statistically significant differences between the A (donor) →B (recipient) or B 
(donor) →A (recipient) groups (Squifflet et al., 2004; Sugiyama et al., 2005; Valli et al., 2009). 
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Anti-A/B blood group antibodies belong to the IgM and IgG isotypes, and their titers, 
which are determined by the direct agglutination test, vary from 1:2 to 1:256 (Issitt & Issitt, 
1979). These titer differences are particularly meaningful in cases of ABO-incompatible 
kidney transplantation (see below).  
4.2 Antiphospholipid antibodies   
Phospholipids (PLs) are known to play an important role in regulating coagulation. They 
form complexes with plasma proteins, such as prothrombin, protein S, protein C, annexin, 
and ǃ2-glycoprotein (Forman et al., 2004; Wagenknecht et al., 2000). These proteins are 
known to be natural anticoagulants (Vaidya et al., 1998). Anti-PL antibodies (APLAs) are 
autologous antibodies, which can cause venous and arterial thrombosis. The binding of 
APLAs to PLs or plasma proteins results in the inhibition of natural anticlotting effects, 
which triggers thrombosis and subsequent fibrin deposition (Knight et al., 1995, Pierangeli, 
2003). There are several groups of APLAs, including anti-cardiolipin antibodies (ACA), anti-
ǃ2-glycoprotein and the lupus anticoagulant (Forman et al., 2004; Vella, 2004). High 
concentrations of APLAs, (as determined by ELISA) and particularly ACAs in association 
with vascular thrombosis or thrombocytopenia result in a clinical disorder that is called 
antiphospholipid syndrome (APLS) (Pierangeli, 2003, Harris & Pierangeli, 2000). An 
analysis of APLA levels in kidney transplant recipients has demonstrated that high titers 
could cause vascular thrombosis and subsequent graft loss. Tolkoff-Rubin’s group, in a 
study that included 337 renal TCs, reported a 25% reduction in the glomerular filtration rate 
in post-transplant patients with low to medium ACA titers. Graft losses were observed in 
two cases where high concentrations of ACA were detected (Forman et al., 2004). 
Furthermore, Knight reported kidney transplant losses on the second day after 
transplantation due to vascular thrombosis that was caused by high concentrations of ACA 
(Knight et al., 1995; Vaidya et al., 1998). Similar results have been reported by Wagenknecht, 
who showed that of 56 failed renal transplant recipients who were maintained on 
hemodialysis prior to transplantation, 32 were positive for APLAs (Wagenknecht et al., 
2000). In summary, preoperative testing for APLAs should be considered for renal TCs with 
a history of maintenance hemodialysis, particularly if the patients have a history of 
thrombotic events. If high concentrations of APLA are detected, the risk of post-transplant 
thrombosis is increased and anticoagulation therapy is a concern. In contrast, no significant 
difference in graft outcomes have been detected between TCs that tested positive or 
negative for APLA if the ACA titers were low (Forman et al., 2004). Anti- ǃ2-glycoprotein 
antibodies were shown to activate endothelial cells (ECs) by affecting NFκB. EC activation is 
accompanied by the upregulation of adhesion molecules, such as vascular cell adhesion 
molecules (VCAM)-1, which represents a potential pathogenic mechanism for cellular 
rejection and accelerated arteriosclerosis (Meroni et al., 2002).  
4.3 Cold agglutinins  
Cold agglutinins (CAs) are autologous antibodies that are usually of the IgMκ subtype but 
are occasionally of the IgG and IgA subtypes. CAs are specific to the Ii (N-
acetyllactoseamine) red blood cells antigenic system. The components of this system present 
on the surfaces of adult human erythrocytes (Diaz et al., 1984; Roelcke, 1974). CA typically 
found at low titers in the peripheral blood of healthy individuals; however, their titers 
increase following infections by Mycoplasma pneumoniae, Epstein-Barr virus, and  
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Fig. 5. Human blood smear. Blue arrows indicate agglutinated red blood cells 
cytomegalovirus. These antibodies are termed CAs because they have a range of thermally-
mediated activities, with the temperature of 0oC being the best (Zilow et al., 1994). CAs may 
also  react with red blood cells at higher temperatures. The range of their reactivity is called 
the thermal amplitude. It has been demonstrated that the maximum thermal amplitude 
temperature is always less than the normal body temperature (37ºC) because their activity 
ceases above this temperature (Diaz et al., 1984; Roelcke, 1989) (Figure 5). CAs destroy 
erythrocytes and can cause autoimmune hemolytic anemia through complement activation. 
In addition, they cause red blood cell aggregation, which, in turn, can lead to 
microcirculation failures (Izzat et al., 1993; Roelcke, 1974, 1989). Activation of the 
complement system at low temperatures can initiate the formation of microemboli and 
microthrombi, which may obstruct capillaries and cause organ ischemia (Roelcke, 1989; Diaz 
et al., 1984; Lobo et al., 1984). Carloss and Tavassoni have reported CA-mediated hyperacute 
kidney failure. They described a patient who developed oliguria and showed increased 
creatinine levels following stomach surgery. The autopsy revealed glomerulonephritis that 
was caused by immune complex deposition. In addition, high levels of CAs of the IgM 
isotype that reacted at 32ºC were also detected (Carloss & Tavassoli, 1980). Sturgill and 
coworkers have reported hyperacute allograft failure in two diseased donor-kidney 
recipients. Both recipients did not have preexisting donor-specific HLA antibodies, and 
tissue typing indicated a six-antigen match. Kidney failure occurred immediately after the 
establishment of vascular anastomosis, and biopsies were performed. Marked red blood cell 
aggregation and fibrin thrombi in capillaries and small arteries were observed in both TCs. 
Elevated CA levels of the IgM isotype were also demonstrated in the serum from the 
recipients. The kidney from one of the recipients was removed 23 days after transplantation 
despite therapeutic intervention (Sturgill et al., 1984). Thus, CAs can cause irreversible 
changes after renal transplantation that may lead to graft loss. High concentrations of CAs 
in the serum may represent a potential explanation for hyperacute graft injury in non-HLA 
sensitized patients. 
www.intechopen.com
 Kidney Transplantation – New Perspectives 24
4.4 Anti-endothelial cells (EC) antibodies 
The importance of DSAs for kidney allograft outcomes was documented many years ago. A 
strong correlation between the development of alloantibodies to mismatched HLAs and 
poor graft outcomes has been reported by many investigators (Adeyi et al. 2005; Baid-
Agrawal & Frei, 2007; Bray & Gebel, 2008; Cai & Terasaki, 2005; Mujtaba et al., 2010; 
Terasaki & Cai, 2005). Recipients of perfectly matched kidney transplants generally survive 
longer and do not frequently develop rejection; however, 2-5% of zero HLA-mismatched 
kidney recipients lose their grafts due to HAR or AMR (Rodriguez et al., 2000). These graft 
failures can be caused by HLA allele-specific antibodies and/or non-HLA antibodies (Ferry 
et al., 1997; Grandtnerova et al., 2008; Lomago et al., 2010; Lucchiari et al., 2000; Perrey et al., 
1998; Sumitran-Karuppan et al., 1997). In 1976, Moraes and Stastny described eight groups 
of non-HLA antigens that are expressed on monocytes and EC (Moraes & Stastny, 1976). 
Subsequent studies have demonstrated that anti-endothelial cell antibodies (AECAs) were 
directed against adhesion molecules, such as ICAM, VCAM, ELAM, PECAM, and vimentin 
(Le Bas-Bernardet et al., 2003; Lucchiari et al., 2000). Antibodies against the protein Tie2, 
which is one of tyrosine kinase receptors that is expressed on vascular endothelium, have 
also been described (Peters et al., 2004). Unlike MHC, the genes coding non-HLAs are not 
located on the 6th chromosome (Kalil et al., 1989). This fact offers an explanation for the 
rejection of HLA-identical grafts. Indeed, transplant recipients from HLA-identical siblings 
with no PRA had considerably longer graft survival times in comparison to those who had 
anti-HLA antibodies (Opelz, 2005). The vascular endothelium of transplanted kidneys and 
other organs is the first line of defense between the allograft and the host immune system. 
Similar to classical MHC antigens, the non-HLAs represent immune system targets, and 
AECAs appear to be clinically important as a potential risk factor for AMR (Han et al., 2009; 
Pober et al., 1996; Rodriguez et al., 2000; Vasilescu et al., 2004; Yard et al., 1993; 
Vanderwoude et al., 1995). FCCM analysis using peripheral blood EC for the detection of 
AECAs has been recently described. This method was shown to be reliable for identifying 
patients at risk for AMR that is mediated by non-HLA antibodies (Alheim et al., 2010; 
Breimer et al., 2009). 
4.5 Antibodies against MHC class I chain-related antigens (MIC) 
Another group of non-HLAs are represented by non-classical MIC antigens A (MICA) and B 
(MICB). These proteins are expressed on endothelial cells, fibroblasts, keratinocytes, and 
monocytes (Zwirner et al., 2006). In contrast to the non-HLAs described above, MICs are 
polymorphic (MICA has 40 alleles, MICB has 23 alleles), and their gene family is located on 
the 6th chromosome close to the HLA-B locus. The presence of antibodies against these 
antigens has been demonstrated to be associated with inferior kidney graft outcomes 
(Rebellato et al., 2006). Relatively high frequencies (26%) of anti-MICA antibodies have been 
reported in recipients with anti-HLA antibodies who lost their kidney grafts because of 
AMR (Mizutani et al., 2005; Mizutani et al., 2006). In summary, non-HLA antigens are 
expressed on graft EC but not on lymphocytes, which are routinely used for CM. Antibodies 
that are directed against these antigens, produce different types of rejection, including HAR, 
AMR, and chronic allograft nephropathy (CAN). Therefore, the detection of AECAs and 
anti-MIC antibodies in TCs may provide insight into unexplained graft rejection, 
particularly in recipients without DSAs and those who have received zero HLA-mismatched 
kidneys.  
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5. The significance of alloantibody concentration, isotype and subtype 
When the initial work up of a potential renal TC is performed, the following important 
questions regarding humoral immunity must be answered. Does this recipient have anti-
HLA antibodies? If so, what is the PRA? Are these antibodies donor-specific (DSAs)? What 
is the isotype of the DSAs? How much DSAs does this particular TC have? The rationale for 
obtaining this information is related to clinical studies, which have universally 
demonstrated that pre-existing DSAs can cause HAR, accelerated or AMR, and CAN (Al-
Lamki, 2008; Bartel et al., 2007; Bishay et al., 2000; Bohmig et al., 2008; Cornell LD et al., 2008; 
Ghasemian et al., 1998; Grandtnerova et al., 1995; Lefaucheur et al., 2009; Lobo et al., 1995; 
Terasaki & Cai, 2008; Racusen et al., 1998). The earliest method that was used to routinely 
detect anti-HLA antibodies was the complement-dependent cytotoxicity assay (CDC). This 
technology has a relatively low sensitivity (see below), wherein it identifies anti-HLA class I 
antibodies using a panel of HLA-typed lymphocytes or DSA class I and class II antibodies, 
which are obtained from patient serum and donor lymphocytes at high concentrations. 
Transplanting kidneys to recipients that have been found to have DSAs by CDC generally 
results in irreversible HAR. The CDC assay is able to detect anti-HLA antibodies of both the 
IgG and IgM isotypes. Discrimination between the two isotypes is accomplished by using 
heating or reducing agents, such as dithiothreitol (DDT) or dithioerythritol (DTE). These 
compounds destroy disulfide bonds between heavy chains of IgMs and abolish their 
reactivity. The identification of the isotypes of DSAs is important because they differentially 
influence graft survival (Schonemann et al., 1998; Stastny et al., 2009). Indeed, DSAs of the 
IgM isotype are generally not believed to be detrimental to renal allografts (McCalmon et al., 
1997; Schonemann et al., 1998; Fredrich et al., 1999); however, there have been reports of 
DSAs of the IgM isotype that mediate HAR and decrease the survival of kidney transplants 
(Demirhan et al., 1998; Stastny et al., 2009). Many investigators have reported the 
distribution of DSA isotypes/subclasses in kidney TCs. Arnold and colleagues have 
demonstrated the usefulness of ELISA in the detection of the IgG (IgG1, IgG2, IgG3, and 
IgG4) and IgA (IgA1 and IgA2) subtypes in kidney TCs (Arnold et al., 2005, 2008). These 
investigators have observed considerably higher frequencies of IgA1 and IgA2 
alloantibodies in retransplant patients than in first-transplant recipients (Arnold et al., 2008). 
Kerman (Kerman et al., 1996) and Koka (Koka et al., 1993) have reported the non-
complement fixing of IgG2/IgG4 and IgA antibodies to have a beneficial effect on kidney 
graft survival. Results from our transplant center have shown uneventful kidney graft 
outcomes in three recipients with high levels of pre-existing DSAs. Subsequent IgG subtype 
analysis revealed that more than 50% of these antibodies were of the IgG2/IgG4 isotype 
(Lobashevsky et al., 2010). It is generally accepted that low (CDC assay-negative) 
concentrations of DSAs of the IgG isotype are not a contraindication for transplantation, 
provided that pre- and post-transplantation desensitization (DS) (see below) and proper 
DSA monitoring are used (Bohmig et al., 2008; Bray, 1994; Christiaans et al., 1998, 2000; 
Graff et al., 2009; Martin et al., 2003; Patel et al., 2007; Reinsmoen et al., 2008; Vaidya et al., 
2001). TCs with low DSA concentrations are considered to be medium risk patients due to 
higher AMR frequencies over a long-term (>5 years) follow up period in comparison to 
negative-DSA recipients (Gebel et al., 2009; Jordan et al., 2004, 2006;  Reinsmoen et al., 2008; 
Vo et al., 2008). 
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6. Alloantibodies against HLA specificities and their impact on kidney graft 
outcomes  
Because the deleterious effects of DSAs, which are directed against HLA-A, -B, -DRB1, and 
DQB1 molecules, on kidney transplant outcomes have been well documented (Abe et al., 
1997; Adeyi et al., 2005; Baid-Agrawal & Frei, 2007; Billen et al., 2009a, 2009b; Bohmig et al., 
2008; Cai et al., 2006a, 2006b; Christiaans et al., 1998; Dunn et al., 2010; Gebel et al., 2009; 
Ghasemian et al., 1998; Kerman et al., 1997; Lederer et al., 1996; Lefaucheur et al., 2009; 
McKenna et al., 2000; Schonemann et al., 1998; Scornik et al., 1992; Terasaki, 2003; Terasaki & 
Cai, 2005; 2008), this section of the review is focused on the role of antibodies against 
additional HLAs, such as C, non-DRB1 (DRB3, DRB4, and DRB5), DQA1, DPB1, and DPA1. 
This group of molecules are classical MHC antigens, meaning that, by definition, they are 
able to elicit cellular and humoral immune responses and present non-self antigens to CD8 
(cytotoxic T lymphocytes) and CD4 (helper) T cells. In comparison to other classical HLAs, 
these proteins are less polymorphic (Marsh et al., 2000).   
6.1 Anti-HLA-C locus alloantibodies 
The immunobiology of the HLA-C locus is not well defined. One of the features of this 
MHC antigen is its low (~10%) cell membrane expression in comparison to HLA-A and 
HLA-B proteins. In addition, the products of HLA-C locus genes are not expressed on 
platelets (Zemmour & Parham, 1992). During the last decade, several reports have 
addressed their role in clinical transplantation. Kidney transplant failures and graft losses 
due to DSAs that are directed against mismatched HLA-C have been reported by 
Worthington (Worthington et al., 2003) and Qasi (Qasi et al., 2006). T cell-positive FCCM 
due to anti-HLA-C antibodies that have been detected by solid phase Luminex technology 
(see below) has been reported by Stastny (Stastny et al., 2006). These investigators have also 
discovered that, to produce a positive FCCM, the median fluorescence intensity (MFI) 
values of anti-HLA-C antibodies must be significantly higher that those produced by 
antibodies against HLA-A and –B. The considerable influence of anti-HLA-C antibodies on 
kidney allocation and graft outcomes has been noted in a recent review of Gebel and Bray 
(Gebel and Bray, 2010).  
6.2 Anti-HLA-DRB3, -DRB4, -DRB5, -DQA1, and -DP loci alloantibodies 
The immunological role of mismatches at HLA-non-DRB1, HLA-DQA, and HLA-DP loci in 
renal transplantation is currently under investigation. The impact of these mismatches on 
graft survival depends on the level of expression, immunogenicity and distribution within 
renal tissue. Kidney glomerular epithelium and mesangium constitutively express HLA-
DRB determinants (Hart et al., 1981; Williams et al., 1980). Using an immunofluorescence 
technique, Fuggle and colleagues were able to detect the aforementioned antigens on 
glomerular endothelium, tubular capillaries and cortical and medullary tubules (Fuggle et 
al., 1983). They also found considerable variation in the expression of HLA-DR by proximal 
tubular cells. Interestingly, as was later reported by Müller, these cells lack HLA-DQ and 
HLA-DP antigens (Müller et al., 1989). Muczynski and colleagues, using three-laser 
multicolor FC analysis, have demonstrated the co-expression of HLA-DR, -DQ, and –DP 
proteins in renal microvascular cells (Muczynski et al., 2003). Subsequent studies have 
shown that all class II genes are expressed, whether constitutively or upon induction, at the 
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following levels in decreasing order: DR>DP>DQ (Guardiola & Maffei, 1993). In addition, 
the degree of cell surface expression largely depends on the cytokine milieu, particularly 
TNFǂ and IFNǄ as well as the activity of the CIITA (class II, major histocompatibility 
complex, transactivator) transcription factor (Guardiola & Maffei, 1993; Muczynski et al., 
2003). The impact of promoter activity on the haplotype expression of HLA class II DRB1-
DRB3, DRB1-DRB4, and DRB1-DRB5 has been investigated by Vincent and colleagues. 
These investigators, using a competitive PCR methodology, analyzed the transcriptional 
levels of these genes and have shown that DRB1-DRB3 (serologically DR52) haplotypes have 
the highest levels of promoter activity, followed by DRB1-DRB4 (serologically DR53) and 
DRB1-DRB5 (serologically DR51) (Vincent et al., 1996). It is necessary to mention that the ǂ 
chains of HLA-DQ and –DP heterodimers are polymorphic, which is unlike the ǂ chain of 
DR (only two alleles have been reported thus far). This may have a significant impact on 
graft outcomes due to potential antibody production in cases where the donor and recipient 
are HLA-DQA and/or HLA-DPA mismatched. Johnson and colleagues have described the 
first case of anti-HLA-DP single-allele antibody development. These investigators have 
reported an increase in HLA-DP-specific alloantiserum in a recipient who received multiple 
immunizations of intradermal injections of mononuclear cells from a healthy donor 
(Johnson et al., 1986). Subsequent studies have not shown a significant effect of HLA-DP 
mismatches on graft outcomes in first transplant recipients; however, a considerable 
reduction in graft survival time was observed in retransplant patients (Arnold et al., 2005; 
Laux et al., 2003; Mytilineos et al., 1997; Qiu et al., 2005; Rosenberg et al., 1992). In kidney 
transplantation from deceased donors, a B cell-positive FCCM due to HLA-DP DSA was 
observed to result in adverse graft outcomes (Goral et al., 2008; Piazza et al., 2006; Vaidya et 
al., 2007). Kamoun and coworkers have reported successful kidney transplantation in a 
regraft patient, who showed positive FCCM due to HLA-DP DSAs, by using intensive 
immunosuppressive therapy (Kamoun et al., 2006). The role of pre-existing anti-HLA-DQA1 
antibodies in kidney transplantation is still uncertain. Results from our transplant center 
have demonstrated uneventful graft outcomes in retransplant kidney recipients who had 
high concentrations of HLA-DQA1*05 DSAs (Lobashevsky et al., 2010). Paul Terasaki’s 
group reported a rejection episode in a kidney transplant recipient due to HLA-DQA1*02:01 
DSAs (Deng, 2008). These investigators used homozygous lymphoblastoid B cell lines for 
antibody absorption to demonstrate reactivity to a single DQA1/DQB1 epitope that is 
shared by multiple DQ determinants. Similar results were obtained by Tambur and 
coworkers, who reported the presence of antibodies in the pre-transplant serum of kidney 
TCs that were directed toward conformational changes that had been generated by a 
combination of DQǂ and DQǃ-chains (Barabanova et al., 2009). In summary, the 
immunogenicity of HLA-non-DRB1, HLA-DQA, and HLA–DP antigens has been 
demonstrated by many investigators (Lobashevsky et al., 2011; Arnold et al., 2005a, 2005b; 
Barabanova et al., 2009; Duquesnoy et al., 2008; Duquesnoy & Askar, 2007; El-Awar et al., 
2009; Laux et al., 2003; Qiu et al., 2005; Rosenberg et al., 1992). DSAs against these 
determinants have appeared to be less clinically significant in comparison to anti-class I and 
anti-DRB1 antibodies. They cause graft failure at significantly lower rates, and 
transplantation in individuals with a positive CM that was caused by antibodies against the 
aforementioned HLA determinants is less deleterious than that when a positive CM that is 
caused by anti-DRB1 antibodies is involved. One potential explanation for this is a lower 
complement binding activity in comparison to anti-DRB1 or anti-class I DSAs (Bartel et al., 
2007; Fuller et al., 1999; Scornik et al., 1992); however, anti-HLA-non-DRB1, HLA-DQA, and 
www.intechopen.com
 Kidney Transplantation – New Perspectives 28
HLA-DP antibodies may need to be evaluated in retransplant recipients for matching and 
graft outcomes. 
7. Methodological considerations of anti-HLA antibody detection 
Antibodies against HLA can be detected by many techniques, which differ in sensitivity. 
This section of the review is devoted to highly sensitive FC and solid-phase methods, which 
employ live cells or purified HLA proteins, respectively. These methods are currently used 
worldwide for pre- and post-transplant alloantibody monitoring. Due to their high 
sensitivities, these techniques allow investigators to detect low concentrations of anti-HLA 
antibodies, which may be missed by low-sensitivity methods, such as CDC (Aubert et al., 
2009; Fuggle & Martin, 2008; Fujita et al., 1997; Gebel & Halloran,  2010; Grandtnerova et al., 
1995; Haririan et al., 2009; Jordan et al., 2006; Kerman et al., 1996; Lobo et al., 1995; Lucchiari 
et al., 2000; Susal & Opelz, 2002; Terasaki & Cai, J 2005, 2008; Yard et al., 1993). 
7.1 Flow cytometry cell based alloantibody analysis 
FC cell-based technology has been introduced in two variations: donor-specific CM 
(Garovoy et al., 1983) and anti-HLA antibody screening using a pool of Epstein-Barr virus 
(EBV)-transformed B lymphoblastoid cells or peripheral blood lymphocytes (Harmer et al., 
1993; Shroyer et al., 1995). This assay uses a laser beam to detect alloantibodies. The 
intensity of the signal that is produced by secondary anti-human antibodies that have been 
conjugated to fluorochrome is proportional to the amount of bound anti-HLA antibodies 
and can be interpreted as the percent of reactive antibodies or PRA. The FCCM assay is the 
most important immunological test that is performed in transplantation because it allows 
for both the detection and quantification of DSAs (Bray, 1994, 2001, 2004; Bray et al., 1989; 
Christiaans et al., 1998; Dunn et al., 2010); however, the presence of autologous antibodies, 
non-HLA antibodies, or mono- and poly-clonal IgG antibodies that are used for 
immunosuppressive therapy in the recipient serum have significantly hampered the 
interpretation of the FCCM results (Lobashevsky et al., 2000; Rodriguez et al., 2000; Scornik 
et al., 1997). These problems were eliminated with the introduction of solid-phase assays.  
7.2 Solid-phase alloantibody analysis 
Solid-phase technology uses purified HLA class I and/or class II proteins that are attached 
to an artificial substrate or matrix. These assays offer significantly higher sensitivities and 
specificities than cellular methods (Fuggle & Martin, 2008; McKenna et al., 2000; Smith & 
Rose, 2009). The enzyme-linked immunosorbent assay (ELISA) was the first solid-phase 
analysis that was developed for antibody screening and specificity determination (Buelow et 
al., 1995). In this assay, HLA molecules are bound to the wells of plastic trays, and positive 
reactions are measured by the color signal intensity, which is produced by enzymes that 
have been conjugated to anti-human antibodies followed by the addition of substrate to the 
wells. Subsequent studies have shown that the ELISA methodology was less sensitive than 
FC methods (Arnold et al., 2004; Christiaans et al., 2000; Kerman et al., 1996; Lefaucheur et 
al., 2009; Schonemann et al., 1998; Smith & Rose, 2009). FC solid-phase assays use 
microspheres that have been coated with soluble HLA proteins, which can be extracted from 
a single cell line for specificity analysis or mixed for PRA analysis (Flow PRASpecific, 
FlowPRA, One Lambda) (Pei et al., 2003). LUMINEX bead technology incorporates 
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microparticles that have been conjugated to varying amounts of two dyes, which enables the 
identification of 100 sets of beads. HLA-specific alloantibodies are detected via addition to a 
reaction mixture of secondary PE-conjugated anti-human antibodies. Because each group of 
beads can be identified by the amount of conjugated fluorochrome, it is possible to identify 
which HLAs have bound antibodies. The original assay was introduced as a combination of 
beads that were coated with HLA proteins that had been extracted from individual cells. 
More recently, with the development of recombinant HLA proteins, LUMINEX technology 
produced microparticles that were covered with a single class I or class II HLA. This 
methodological approach revolutionized antibody specificity analyses, particularly in highly 
sensitized patients (Billen et al., 2009; El-Awar et al., 2005, 2006; Lobashevsky & Higgins, 
2009; Mujtaba et al., 2010; Pei et al., 2003; Zeevi et al., 2009). The considerably higher surface 
density of HLAs on the microbeads in comparison to that achieved on lymphocytes (Jar 
How Lee, personal communication, 2010) makes the LUMINEX single-antigen (SA) 
methodology extremely specific and highly sensitive, enabling investigators to detect very 
low concentrations of HLA-directed antibodies. The latter is particularly important from a 
clinical point of view. Yet, how strong must the DSA signal that is produced by a SA 
Luminex assay be to generate a positive FCCM? In order to address this question, 
correlation analyses between MFI values that are detected by SA beads and signals that are 
detected by lymphocyte FCCM must be performed (Lobashevsky & Higgins, 2009; Martin et 
al., 2003; Mizutani et al., 2006; Ozawa et al., 2006; Poli et al., 2009; Qasi Y et al., 2006; Stegall 
et al., 2009; Terasaki & Cai, 2005; Zachary et al., 2005, 2009). At our transplant center, the 
positive MFI thresholds for anti-HLA class I and class II antibodies, which are detected via 
SA technology and produce positive FCCMs, are 2800 and 3500, respectively (predictive 
value >95%) (Figure 6).  
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Fig. 6. HLA class I (A) and class II (B) antibody specificity determination using Luminex 
platform solid phase methodology. Vertical axis indicates mean fluorescence intensity 
(MFI), horizontal axis indicates single HLA class I and class II proteins conjugated to the 
beads. Blue lines determine positive cut-offs (i.e. MFI value levels producing positive FC 
CM results when donor lymphocytes are used) established by our laboratory.   
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This effect is cumulative when multiple DSAs are being considered (Lobashevsky & 
Higgins, 2009). There are a few caveats regarding the SA LUMINEX analysis. First, as 
mentioned above, the density of HLA molecules on the bead is significantly higher than that 
on lymphocyte (5 x 104 - 105 molecules per cell) or endothelial cells. Therefore, even a minor 
admixture of anti-HLA antibodies of the IgM isotype may cause false negative results. To 
overcome this obstacle, serum DTT-treatment is recommended (Zachary et al., 2009). More 
recently, discrepant results between negative FCCMs and highly reactive DSAs that have been 
determined by SA Luminex have been reported. In this study, strong DSA anti-B44 (high-
resolution donor HLA-B locus typing confirmed DSAs) reactivity was determined in the 
recipient serum by SA beads; however, negative T- and B- cell FCCM was observed when 
donor lymphocytes were used. Biochemical modification (denaturing) of HLA proteins during 
the bead conjugation process can account for this discrepancy. In comparison to unmodified 
HLAs, denatured HLAs have a higher affinity for DSAs and, when present in large amounts, 
they produce strong false positive signals. To rule out antibodies against denatured HLAs, an 
acid treatment is used. Antibodies against denatured HLA proteins are likely present when no 
difference in MFI values is observed between treated and untreated beads (Gandhi et al., 
2011). Several years ago, solid-phase bead-based CM assays were developed at the Tepnel 
Lifecodes Corporation. This technique utilizes synthetic micro-particles that have been labeled 
with different fluorochromes and coated with capturing antibodies that are directed to non-
polymorphic domains of class I (ǂ3) and class II (ǃ2) HLA molecules. Donor HLAs (lysate) are 
extracted from lymphocytes and incubated with the beads. Recipient serum and anti-human 
antibodies are then added. Fluorescent signals identify each set of microparticles as well as the 
reporter dye that is linked to the secondary antibodies. In this way, it can be determined if the 
potential recipient has class I or/and class II DSAs. A comparative analysis of solid-phase and 
lymphocyte CM assays, which have been performed by our group, have demonstrated a 100% 
agreement when sera with anti-HLA-A, -B, and -DR antibodies were used (Lobashevsky  
et al., 2009). 
Complement activation following antibody/HLA interactions is clinically important in two 
ways. First, the classical pathway of complement activation causes C4d deposition in 
peritubular capillaries and is usually associated with graft cell damage and poor graft 
outcomes. Second, high concentrations of pre-existing IgG DSAs (positive CDC CM) are a 
risk factor for HAR. Over the course of the last decade, the implementation of various DS 
protocols (see below) for highly sensitized patients has resulted in successful kidney 
transplantation in patients with positive FCCMs that have been caused by DSAs; however, 
the graft outcome and survival times appear to depend on several parameters, e.g., the 
amount of DSAs that are producing a positive FCCM, their isotype, the cytokine profile of 
the recipient and others (Akalin & Bromberg, 2005; Bray 1994; Christiaans et al., 1998; Graff 
et al., 2009; Horsburgh et al., 2000; Lobashevsky et al., 2010; Martin et al., 2003; Mujtaba et 
al., 2010; Qasi et al., 2006; Scornik et al., 1997; Worthington et al., 2003; Zachary et al., 2005). 
It has recently been demonstrated that some DSAs that are detected by FC, but not by CDC 
(FC pos/CDC neg), are able to activate complement. Bartel and colleagues demonstrated, 
using SA bead technology and antibodies against C4d, C1q and C3b, that inferior graft 
outcomes were observed more frequently in recipients whose DSAs were able to bind the 
complement (Bartel et al., 2007). Similar findings have been reported by others (Bohmig et 
al., 2008; Yabu et al., 2010). Saw and coworkers have developed a comprehensive procedure 
that determines cell death and antibody binding in a single assay by using TOPRO-3 
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staining for apoptotic cells (Saw et al., 2008). In summary, solid-phase analysis represents a 
powerful tool for anti-HLA antibody analysis and has several advantages over other assays. 
First, due to its superior sensitivity and specificity, low concentrations of DSAs pre- and 
post-transplant can be detected. Second, this technology does not require viable cells. Third, 
it detects only anti-HLA antibodies. 
8. Desensitization is a method for the removal of pre-existing anti-HLA 
antibodies  
The development of anti-HLA antibodies represents a significant barrier to transplantation 
for many patients because of the high risk of AMR-mediated graft failure (Adeyi et al., 2005; 
Zachary,  2009; Bray, 1994, 2001; Haririan et al., 2009; Yard et al., 1993; Zeevi et al., 2009). 
Historically, transplantation for such patients was possible only when a donor could be 
found whose tissues did not express any HLA that the recipient produced antibodies 
against.   
8.1 Intravenous immunoglobulin (IVIG) 
During the last two decades, however, protocols using pooled human IVIG and/or 
plasmapheresis (PP) have been shown to eliminate some or all DSAs  (Jordan et al., 2004, 
2006; Reinsmoen et al., 2008; Rogers et al., 2011; Thielke et al., - 2005; Claas et al., 2004; Gloor 
et al., 2004; Stegall et al., 2009; Leong et al., 2008). Furthermore, a beneficial effect of 
IVIG/PP treatment for AMR has been reported by many transplant centers (Akalin et al., 
2008; Furth et al., 1999; Lehrich et al., 2005; Rifle & Mousson, 2003; Toyoda et al., 2004; Vo et 
al., 2010). More recently, it was reported that sensitized TCs require different DS regimens to 
reduce DSA levels, including varying the IVIG dose and the number of PP cycles (Cai & 
Terasaki, 2005; Thielke et al., 2005; Ferrari-Lacraz et al., 2006; Glotz et al., 2004; Rogers et al., 
2011). Subsequent studies have demonstrated that susceptibility to IVIG/PP DS depends on 
immunoregulatory mechanisms, such as polymorphisms in cytokine genes, the frequency of 
regulatory cells, and hormonal backgrounds (Figure 7) (Glotz et al., 2004; Lobashevsky et al., 
2009; Rogers et al., 2011; Zachary et al., 2003; Bas et al., 1998; Di Genova et al., 2006, 2010; 
Jiang & Lechler, 2003, Amu et al., 2007; Anderson et al., 2000; Hill & Sarvetnick, 2002;  Kalil 
et al., 1989; Stasi et al., 2008; Stastny P et al., 2006; Yoo et al., 1995).  
Furthermore, the efficacy of DS has been reported to be different for DSAs and third-party 
HLA antibodies. For example, Andrea Zachary’s group reported a considerable reduction in 
DSAs in a TC that had been subjected to IVIG DS in comparison to the level of 
alloantibodies against a third party (Zachary et al., 2003). Higgins et al. observed similar 
results (Higgins et al., 2009). Our data are also in agreement with these findings; however, 
they did not reach statistical significance (Lobashevsky et al., 2009). IVIGs are commercially 
prepared products that contain IgGs (>90%) that are derived from human plasma that has 
been pooled from tens of thousands of healthy individuals. In addition, IVIGs contain 
antibodies against CMV, T cell receptor idiotypes, and some cytokines, including GM-CSF 
and IL-1ǃ (Jordan et al., 2003). The primary mechanisms of IVIG-mediated 
immunomodulation are summarized as the following: first, the inhibition of complement 
binding through blockage of C3 convertase (Kazatchkine & Kaveri, 2001; Lutz et al., 2004; 
Watanabe & Scornik, 2005); second, the neutralization of circulating antibodies through 
idiotype-anti-idiotype interactions (Glotz et al., 2004; Jordan et al., 2004, 2006; Watanabe & 
Scornik, 2005); third, the inhibition of IL-2 and IFN–Ǆ secretion (Glotz et al., 2004; 
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Fig. 7. PRA changes (▬■▬ class I, ▬▲▬ class II) in susceptible (pink line) and resistant 
(blue line) to DS TCs after sequential courses of IVIG/PP. Black arrows indicate IVIG 
administration. 
Kazatchkine & Kaveri, 2001); forth, the inhibition of T cell proliferation through anti-T cell 
receptor activity (Jordan et al., 2006; Klaesson et al., 1993); and fifth, the downregulation of 
antigen that presents cell (APC) activity, which causes the inhibition of T cell activation 
through Fc receptor-mediated interactions (Bayry et al., 2003). Clinically, IVIG are known to 
be well tolerated; however, adverse events, such as osmotic nephropathy and hemolytic 
anemia in non-O blood type patients, have been reported (Banerjee et al., 2003). Commercial 
preparations of IVIG contain different concentrations of anti-A and anti–B 
isohemagglutinins. The highest concentrations have been found in Privigen (1:64 and 1:32 
titers of IgG anti-A and anti-B, respectively). In contrast, Carimune contains the lowest titers 
of anti-A and anti-B isohemagglutinins; however, this preparation is hyperosmolar, which 
limits its use in patients who are not on dialysis or present with an increased risk of 
thrombosis (Kahwaji et al., 2009). IVIG immunomodulation should be considered for 
treatment in non-O blood type TCs due to the increased risk of IVIG-induced hemolytic 
anemia. Anti-A and/or anti-B isohemagglutinin titers in IVIG preparations are particularly 
meaningful when AB blood type-incompatible kidney transplantation is an option due to 
the increased risk of anti-A/B antibody-mediated graft failure. 
8.2 Rituximab 
A combination of IVIG and Rituximab (Rituxan) (chimeric humanized monoclonal 
antibodies against the CD20 marker for B lymphocytes) DS has been shown to effectively 
reduce DSAs. The rates of the conversions of positive to negative CDC CMs and reductions 
of MCS in FCCMs were higher in comparison to cases where DS was used without Rituxan 
(Lefaucheur et al., 2009; Rogers et al., 2011; Vo et al., 2008; Vo et al., 2010). Rituxan affects 
mature B-cells (CD20+, IgG-, CD19+) and at lesser degree memory B cells (CD20+, CD27+, 
IgG+) and prevents the formation of plasma cells (CD20-, CD19- IgG-, CD38+, CD138+) de 
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novo. A beneficial effect of Rituxan and IVIG for AMR treatment in kidney transplantation 
was reported by Vo et al. (Vo et al., 2010) and Lefaucheur et al. (Lefaucheur et al., 2009). The 
IVIG/Rituxan treatment resulted in more effective DSA removal, likely by blocking the 
indirect pathway of mismatched HLA protein recognition. In this case, mature B cells 
function as APCs and present donor HLA-processed peptides to the host T helper cells. The 
latter become activated and stimulate the differentiation of B memory and mature B cells 
into antibody-producing short- and long-living plasma cells by secreting IL-4, IL-6, IL-1ǃ, 
GM-CSF, and IL-17 (Yoo et al., 1995). 
8.3 Plasmapheresis (PP) or therapeutic plasma exchange (TPE) 
As mentioned above, PP [or therapeutic plasma exchange (TPE)] is a necessary component 
of immunomodulation/DS or AMR therapy because it physically removes anti-HLA 
antibodies from the circulation. This function can also be applied to paraproteins, polyclonal 
autoantibodies, or antibodies in immune complexes. Although PP implementation results in 
a considerable reduction of anti-HLA antibodies, the effect can only be achieved after 
multiple cycles of treatment in highly sensitized TCs. This is presumably because of IgG 
equilibration between the intravascular and extravascular spaces. For example, depleting 
the total body IgGs by 85% was observed to require five exchanges of 1.25 times the plasma 
volume (Weinstein 2003). In addition, the removal of immunoglobulins by PP may be 
followed by an increase in specific antibody titers (the rebound effect) to levels that are even 
higher than those at baseline. The mechanism of this phenomenon is through biofeedback 
stimulation to increase IgG synthesis (Dau P 1995).  
8.4 The removal of anti-AB blood group antibodies    
Historically, ABO incompatibility (ABOi) is considered to be a contraindication for kidney 
transplantation due to irreversible HAR of the graft. The shortage of kidney donors has led 
to an increasing gap between the number of patients who are waiting for kidney 
transplantation and the number of available kidney donors. An expansion of the kidney 
donor pool can be achieved by performing transplantations despite the immunological 
barrier of ABOi. Successful kidney transplantation from A2 (A2B or A2O) donors to B or O 
recipients was reported (Alkhunaizi, 2006; Bryan et al., 1998; Nelson et al., 1998). Bryan and 
colleagues demonstrated that the graft outcomes in A2 donor (deceased and living) kidney 
recipients were comparable to ABO-compatible transplants (Bryan et al., 1998). Subsequent 
investigations have shown that the success of A2 donor transplantation depends on anti-A1 
and anti-A2 IgG isohemagglutinin titers in the recipient serum prior to transplantation. A1 
and A2 blood group antigens differ qualitatively and quantitatively (see above). Indeed, for 
transplantation from A2 donors into B or O recipients, anti-A1 IgG titers that were above 
1:128 have been shown to represent a significant risk factor for AMR (Squifflet et al., 2004; 
Tyden et al., 2010; Valli et al., 2009; Warren et al., 2004). In addition, Alkhunaizi reports that 
up to 8% of A2 individuals have anti-A1 IgG antibodies in their sera (Alkhunaizi, 2006). 
Anti-A1 IgG antibody titers of less than or equal to 1:8 have been considered to be a cut-off 
for assuming a low risk of AMR (Gloor & Stegall, 2007; Jordan et al., 2009; Rydberg et al., 
2007; Warren et al., 2004). Additional therapeutic measures are required when titers of anti-
A1 IgG antibodies are high, such as plasma exchange that is accompanied by a bimonthly 
monitoring of anti-A1 titers (Montgomery & Locke, 2007; Tobian et al., 2009; Tyden et al., 
2010; Winters et al., 2004).  
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About a decade ago, more A1 to B, B to A1, and A1 or B to O ABOi kidney transplants were 
initiated to increase the potential donor pool. Reports from Europe, Japan and the United 
States have demonstrated successful ABOi kidney transplantation from both living and 
deceased donors. Tanabe reported a relatively high percentage of 1- and 2-year graft 
survivals (96% and 94%, respectively) after using 3-4 pre-transplant PPs along with 
splenectomy and/or Rituximab (Tanabe, 2007; Beimler & Zeier, 2007).  A new protocol for 
ABOi kidney transplantation was introduced in Sweden in 2001. In this method, 
immunoabsorption columns that were filled with A/B oligosaccharides (Glycosorb, 
Glycorex Transplantation AB, Lund, Sweden) were used instead of PP in order to remove 
anti-A or anti-B antibodies. In addition, Rituximab was used instead of splenectomy in order 
to prevent rebound effects (Tyden 2007; Valli et al., 2009). These investigators demonstrated 
that anti-AB IgG antibody titers were reduced from 1:2 – 1:128 to 1:1-1:2 after 4-8 cycles of 
immunoabsorption. A rebound effect was observed in only one of eleven recipients after 36 
months post-transplantation. Notably, no differences in graft survival time between ABOi 
and ABO-compatible transplantations were observed (Rydberg et al., 2007; Tyden et al., 
2005). Five years ago, the John Hopkins Transplant Center established a DS protocol for 
ABOi transplantation, which consisted of PP, IVIG and Rituxan administration (Sonnenday 
et al., 2004; Tobian et al., 2009). This immunomodulating strategy included multiple cycles 
of pre-transplant PP so as to reduce anti-A/B antibody titers to <1:16 followed by a single 
dose of Rituximab. The post-transplantation treatment included an additional 3-4 PP/IVIG 
cycles. An analysis of graft outcomes in six ABOi donor/recipient combinations did not 
demonstrate any differences in either creatinine levels or the rate of humoral rejection 
(Sonnenday et al., 2004). More recently, several groups have reported successful 
implementations of the drug Bortezomib (C19H25BN4O4) (Velcade) for DS and AMR 
treatment in kidney transplantation (Everly et al., 2009; Raghavan et al., 2010; Walsh et al., 
2010). Originally, Bortezomib was used for the treatment of multiple myeloma, which is a 
tumor consisting of plasma cells (PCs) (Cavo 2006; Mitchell 2003). The mechanism of action 
for this drug involves proteosome inhibition, which is accomplished by the binding of the 
26S subunit and subsequent apoptosis, through caspase 3/7, in antibody-producing PCs 
(Diwan et al., 2011; Perry et al., 2009; Ruschak et al., 2010). The use of Bortezomib in clinical 
transplantation is advantageous for the specific targeting of long-living 
CD38+/CD138+/CD20- PCs in the bone marrow and secondary lymphoid tissue. 
Subsequent studies have shown that Bortezomib alone had little or no impact on DSA levels 
(Sberro-Soussan et al., 2010); however, when used in combination with PP, IVIG or 
Rituximab, a prominent reduction in class I and class II DSA concentrations were 
demonstrated (Diwan et al., 2011; Everly et al., 2009; Perry et al., 2009). In summary, 
removing DSAs or anti-A/B blood group antibodies expands the donor pool for highly 
sensitized or ABOi kidney TCs; however, these methods introduce several concerning 
issues. First, in the majority of cases, DS does not completely eliminate DSAs. Second, the 
DSA rebound effect presents considerable concern. The rate and intensity of alloantibody 
return depends on multiple factors, including the production of cytokines, hormones, 
frequency immunoregulatory cells, and infection. Third, desensitized patients require 
regular post-transplant DSA monitoring so as to determine if additional 
immunomodulating therapy is necessary. Finally, long-term kidney graft outcomes in 
desensitized recipients are beset with frequent humoral rejection episodes and graft loss 
when compared to DSA-negative TCs. 
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9. The association between post-transplant alloantibody production and 
rejection  
9.1 Antibody-mediated rejection (AMR) or humoral rejection  
AMR is a frequent complication in renal transplant recipients and may develop any time 
after transplantation (Abe et al., 1997; Christiaans et al., 1998; Cornell et al., 2008; Gloor et al., 
2004; Lefaucheur et al., 2009; Matas et al., 2000; Patel et al., 2007; Perrey et al., 1998; Supon et 
al., 2001; Zeevi et al., 2009). Alloantibodies that are produced against donor tissues are 
usually directed against mismatched HLA class I and/or class II antigens, in addition to 
non-HLAs, including MIC and EC antigens (reviewed in Cornell et al., 2008; Smith & Rose, 
2009; Smith, 2007). It is generally accepted that complement-mediated cytolysis is the major 
mechanism of kidney vascular endothelial and parenchymal cell damage. The 
clinicopathological presentation of AMR is characterized by peritubular capillary C4d 
deposition, which is characterized by a rapid rise in serum creatinine and the appearance of 
DSAs in the circulation. C4d is a component of the classical pathway of complement 
activation, which remains in the tissue for several days (Cornell et al., 2008; Haririan et al., 
2009). Peritubular capillary C4d deposition has been demonstrated in 88%-95% of kidney 
transplant recipients who developed class I and class II DSAs (Colvin, 2007); however, AMR 
can occur even without detectable concentrations of DSAs in the circulation, which is likely 
due to their absorption by the kidney graft. The subsequent nephrectomy is usually 
accompanied by a rise in DSAs within several days (Cornell et al., 2008; Duquesnoy, 2008; 
Duquesnoy & Claas, 2007). The detrimental effects of non-HLA antibodies are also 
associated with complement fixing but at a lower degree; however, in the absence of 
complement, anti-MIC antibodies and AECA can activate graft ECs to proliferate, resulting 
in the upregulation of adhesion molecules, such as ELAM, ECAM, and neuropilin-2 
receptor, as well as the production of TGF-ǃ, which stimulates the growth of connective 
tissue fibroblasts [reviewed in (Smith & Rose, 2009)]. Recently, graft accommodation in 
experimental models was described (Aikawa et al., 2003; Jin, 2002; Tabata, 2003). The state of 
accommodation is defined as normal graft function and appearance, which is evaluated by 
light microscopy, in the presence of circulating DSAs (Cornell, et al., 2008). The mechanism 
of accommodation was found to be associated with the upregulation of anti-apoptotic genes, 
such as bcl-2, bcl-xL, and A20. The precise mechanism of accommodation is still under 
thorough investigation. 
9.2 The role of aloantibodies in chronic rejection or chronic allograft nephropathy 
(CAN)  
DSAs also participate in the development of chronic allograft changes, which can be seen in 
glomeruli, vessels, tubules and the interstitium (Cornell et al., 2008; Racusen et al., 1998). 
Their pathological effects therein are mediated by two major processes. First, DSAs cause EC 
damage by complement-dependent cytotoxicity, which is also a mechanism of humoral 
rejection; however, unlike AMR, C4d deposition has been reported in approximately 30% - 
50% of cases (Colvin 2007). Second, the upregulation of fibroblast growth factor receptors 
has been demonstrated in elegant studies that were conducted by E. Reed’s group (Jin, 
2002). These investigators found that the antibody-mediated ligation of class I HLAs triggers 
an activation signal in ECs, resulting in arterial smooth muscle cell and basement membrane 
fibroblast proliferation. As a consequence, the lumen of glomerular arteries is decreased and 
subsequent fibrosis and tissue/organ ischemia develop. 
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10. Conclusions 
1. HLA and non-HLA-specific DSAs play a critical role in the pre- and post-transplant 
monitoring of renal patients. High levels of anti-HLA (high PRA) antibodies are 
generally associated with longer periods of time on dialysis and/or on the transplant 
waiting list until a CM-compatible donor can be found. Post-transplant DSA 
development often leads to AMR, graft deterioration, or eventual loss. 
2. AMR or humoral rejection is mediated by a multi-component mechanism that is 
associated with anti-HLA class I and class II alloantibodies, complement, and T cells 
whose primary targets are graft endothelial and tubular cells. Although complement-
dependent cytotoxicity is the chief mechanism of antibody-mediated graft damage, 
additional biological processes result in EC proliferation, pro-inflammatory cytokine 
production, and apoptosis. Post-transplant DSA development depends on multiple 
factors, including donor-recipient HLA mismatches (epitope levels), recipient HLA-
class II typing, and immunoregulatory mechanisms. Careful analysis of mismatched 
epitopes can predict, with some degree of accuracy, the profile of antibodies that will 
develop post-transplant. The latter is particularly meaningful for subsequent donor 
searches. 
3. The pre-transplant deletion of anti-HLA antibodies, or DS, considerably expands the 
pool of donors for highly sensitized TCs. This therapeutic approach (or 
immunomodulation) often includes combinations of different protocols, including the 
use of PP, IVIG, Rituximab and Bortezomib; however, DS is not a panacea for patients 
with high PRAs, and not all recipients are susceptible to this treatment. In addition, the 
rebound effect is a frequent consequence of this type of immunomodulation. 
Furthermore, all of the aforementioned DS protocols are not free from adverse effects. 
Although the majority of cases show considerable decreases in DSA antibody levels, 
they are not completely eliminated (the rate of antibody production is 1000 
molecule/PC cell/second). These remaining DSAs represent a risk factor for humoral 
graft rejection in long-term follow up. 
4. The development of DSAs is a major obstacle to long-term graft survival. Because of 
this, individual immunosuppression/DS is one of the most hopeful future directions for 
progress in kidney transplantation. This therapeutic approach must incorporate the 
analysis of the genes that are involved in cytokine (IL-12, TNFǂ, IFNǄ) and chemokine 
production, the frequency of T regs and NKT cell production, as well as detailed 
analysis of the alloantibody profiles.  
11. References 
Abe, M.; Kawai, T. & Futatsuyama, K. (1997). Postoperative production of anti-donor 
antibody and chronic rejection in renal transplantation, Transplantation, Vol.63, 
No.11, (n.d.), pp.1616-1619. 
Adeyi, O.; Girnita, A. & Howe, J. (2005). Serum analysis after transplant nephrectomy 
reveals restricted antibody specificity patterns against structurally defined HLA 
class I mismatches. Transplant Immunolology, Vol.14, No.1, (n.d.), pp.53-62. 
Aikawa, A.; Yamashita, M. & Hadano, T. (2003).ABO incompatible kidney transplantation --
immunological aspects, Exp Clin Transplant,  Vol.1, No.2, (n.d.), pp. 112-118. 
www.intechopen.com
 Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney Transplantation 37 
Akalin, E. & Bromberg, J. (2005). Intravenous immunoglobulin induction treatment in flow 
cytometry cross-match-positive kidney transplant recipients. Human Immunology, 
Vol.66, No.4, (n.d.), pp.359-363. 
 Akalin, E.; Dinavahi, R. & Friedlander, R. (2008). Addition of plasmapheresis decreases the 
incidence of acute antibody-mediated rejection in sensitized patients with strong 
donor-specific antibodies. Clinical  Journal of American Society of Nephrology,  Vol.3, 
No.4, (n.d.), pp.1160-1167. 
 Akalin, E. & Pascual, M. (2006). Sensitization after kidney transplantation. Clinical Journal of 
American Society of Nephrology, Vol.1, No.3, (n.d.), pp.433-440. 
Al-Lamki, R.; Bradley, J. & Pober, J. (2008). Endothelial cells in allograft rejection. 
Transplantation, Vol.86, No.10, (November 27), (n.d.), pp.1340-1348.Alheim, M. et al. 
(2010). A flow cytometric crossmatch test for simultaneous detection of antibodies 
against donor lymphocytes and endothelial precursor cells. Tissue Antigens, Vol.75, 
No.3, (n.d.), pp.269-277. 
Alkhunaizi, A. (2006). Renal transplantation across the ABO barrier. Saudi Journal of Kidney 
Disease Transplantation,  Vol.17, No.3, (n.d.), pp.311-315. 
Amu, S. (2007). The human immunomodulatory CD25(+) B cell population belongs to the 
memory B cell pool. Scandinavian Journal of Immunology, Vol.66, No.1, (n.d.), pp.77-
86, ISSN 0300-9475 
Anderson, B. et al. (2000). Induction of determinant spreading and of Th1 responses by in 
vitro stimulation with HER-2 peptides. Cancer Immunology and Immunotherapy, 
Vol.49, No.9, (November 2007), pp.459-468. 
Armitage, R. & Alderson, M. (1995). B-Cell Stimulation. Current Opinion in Immunology, 
Vol.7, No.2, (April 1995), pp.243-247. 
Arnold, M. et al. (2004). Detection and specification of noncomplement binding anti-HLA 
alloantibodies. Human Immunology, Vol.65, No.11, (November 2004), pp.1288-1296, 
ISSN 0198-8859 
Arnold, M. et al. (2005).HLA DQ antibodies in patients awaiting kidney re-transplantation. 
Genes and Immunity,  Vol.6, No.6, (n.d.), p.6, ISSN 81466-4879 
Arnold, M. et al. (2005). Anti-HLA class II antibodies in kidney retransplant patients. Tissue 
Antigens, Vol.65, No. 4, (April 2005), (n.d.), pp.370-378, ISSN 0001-2815Arnold, M. 
et al. (2008). Prevalence and specificity of IgG and IgA non-complement binding 
anti-HLA alloantibodies in retransplant candidates. Tissue Antigens, Vol.72, No.1, 
(July 2008), pp.60-66. 
Aubert V. et al. (2009). Low levels of human leukocyte antigen donor-specific antibodies 
detected by solid phase assay before transplantation are frequently clinically 
irrelevant. Human Immunology, Vol.70, No.8, (n.d.), pp.580-583. 
Baid-Agrawal, S. & Frei, U. (2007). Living donor renal transplantation: recent developments 
and perspectives. Nature Clinical Practice. Nephrology, Vol.3, No.1, (January 2007), 
pp. 31-41, ISSN 1745-8323 
Balan, V. (2008). Long-term outcome of human leukocyte antigen mismatching in liver 
transplantation: results of the National Institute of Diabetes and Digestive and 
Kidney Diseases Liver Transplantation Database. Hepatology. Vol. 48, No.3, 
(September 2008), pp.878-888. 
www.intechopen.com
 Kidney Transplantation – New Perspectives 38
Banerjee, D.; Kupin, W. & Roth, D. (2003). Hemolytic uremic syndrome after multivisceral 
transplantation treated with intravenous immunoglobulin. Juornal of Nephrology, 
Vol.16, No.5, (October 2003), pp.733-735, ISSN 1121-8428 
Barabanova Y.; Ramon, D. & Tambur, A. (2009). Antibodies against HLA-DQ alpha-chain 
and their role in organ transplantation. Human Immunology, Vol.70, No.6, (n.d.), 
pp.410-412. 
Bartel, G. et al. (2007). Determinants of the complement-fixing ability of recipient 
presensitization against HLA antigens. Transplantation, Vol.83, No.6, (n.d.), pp.727-
733. 
Bas, J. et al. (1998). Peripheral blood lymphoid subsets and long-term clinical course of 
kidney recipients: A longitudinal study. Cytometry, Vol.34, No.2, (April 1998), 
pp.103-112,0196-4763 
Bayry, J. et al. (2003). Inhibition of maturation and function of dendritic cells by intravenous 
immunoglobulin. Blood, Vol.101, No. 2, (January 2003), pp.758-765, ISSN 0006-4971 
Beimler J. & Zeier, M. 2007ABO-incompatible transplantation - a safe way to perform renal 
transplantation?, Nephrology, Dialysis, Transplantation, Vol.22, No.1, (January 2007), 
pp.25-27, ISSN 0931-0509 
Benson, M. et al. (2009). Distinction of the memory B cell response to cognate antigen versus 
bystander inflammatory signals. Journal of Experimental Medicine, Vol.206, No.9, 
(n.d.), pp.2013-2025. 
Billen, E. et al. (2009). Donor-directed HLA antibodies before and after transplantectomy 
detected by the luminex single antigen assay. Transplantation, Vol.87, No.4, 
(February 2009), pp.563-569. 
Billen, E.; Christiaans, M. & van den Berg-Loonen, M. (2009). Clinical relevance of Luminex 
donor-specific crossmatches: data from 165 renal transplants. Tissue Antigens, 
Vol.74, No.3, (September 2009), pp. 205-212. 
Bishay, E. et al. (2000). The clinical significance of flow cytometry crossmatching in heart 
transplantation. European Journal of Cardiothorac Surgery, Vol.17, No.4, (n.d.), pp.362-
369. 
Bohmig, G.; Bartel, G. & Wahrmann, M. (2008). Antibodies, isotypes and complement in 
allograft rejection. Curr Opin Organ Transplant, Vol.13, No.4, (n.d.), pp.411-418, 
ISSN 1087-2418 
Bray, R.; Lebeck, L. & Gebel, H. (1989). The flow cytometric crossmatch. Dual-color analysis 
of T cell and B cell reactivities. Transplantation, Vol.48, No.5, (November 1989), 
pp.834-840 
Bray, R. (1994). Flow cytometry crossmatching for solid organ transplantation. Methods in 
Cellular Biology, Vol.41, (n.d.), pp.103-119 
Bray, R. (2001). Flow cytometry in human leukocyte antigen testing. Seminars in Hematology, 
Vol.38, No.2, (April 2001), pp.194-200. 
Bray, R. et al. (2004). Evolution of HLA antibody detection: technology emulating biology. 
Immunological Research, Vol.29, No.1-3, (n.d.), pp.41-54, 
Bray, R. & Gebel, H. (2008). Monitoring after renal transplantation: recommendations and 
caveats. Nature Clinical Practice. Nephrology, Vol.4, No.12, (December 2008), pp.658-
659. 
Breimer, M. et al. (2009). Multicenter evaluation of a novel endothelial cell crossmatch test in 
kidney transplantation. Transplantation, Vol.87, No.4, (n.d.), pp.549-556. 
www.intechopen.com
 Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney Transplantation 39 
Bryan, C.; Shield, C. & Nelson, P. (1998). Transplantation rate of the blood group B waiting 
list is increased by using A2 and A2B kidneys. Transplantation, Vol.66, No.12, (n.d.), 
pp.1714-1717. 
Buelow, R. et al. (1995). Soluble HLA antigens and ELISA - A new technology for 
crossmatch testing. Transplantation, Vol.60, No.12, (December 1995), pp.1594-1599, 
ISSN 0041-1337 
Cai, J. & Terasaki, P. (2005). Humoral theory of transplantation: mechanism, prevention, and 
treatment. Human Immunology, Vol.66, No.4, (April 2005), pp.334-342. 
Cai, J.; Kohanof, S. & Terasaki, P. (2006). HLA-DR antibody epitopes. Clinical Transplantation, 
Vol.20, No.1, (n.d.), pp.103-114. 
Cai, J.; et al. (2006). Development of nondonor-specific HLA-DR antibodies in allograft 
recipients is associated with shared epitopes with mismatched donor DR antigens. 
American Journal of Transplantation, Vol.6, No.12, (December 2006),pp.2947-2954, 
ISSN 1600-6135 
Carloss, H. & Tavassoli, M. (1980). Acute renal failure from precipitation of cryoglobulins in 
a cool operating room. Journal of American Medical Association, Vol.244, No.13, 
(September 1980), pp.1472-1473, 
Cavo, M. (2006). Proteasome inhibitor bortezomib for the treatment of multiple myeloma. 
Leukemia, , Vol.20, No.8, (August 2006), (n.d.), pp.1341-1352, ISSN 0887-6924 
Christiaans, M. (2000). Detection of HLA class I and II antibodies by ELISA and 
complement-dependent cytotoxicity before and after transplantation. 
Transplantation, Vol.69, No.5, (March 2000), pp.917-927, ISSN 0041-1337 
Christiaans, M. et al. (1998). Donor-specific antibodies after transplantation by flow 
cytometry - Relative change in fluorescence ratio most sensitive risk factor for graft 
survival. Transplantation, Vol.65, No.3, (n.d.), pp.427-433, ISSN 0041-1337 
Claas, F. et al. (2005). Differential immunogenicity of HLA mismatches in clinical 
transplantation. Transplant Immunology,  Vol.14, No.3, (n.d.), pp.187-191. 
Claas, F. & Doxiadis, I. (2009). Human leukocyte antigen antibody detection and kidney 
allocation within Eurotransplant. Human  Immunology, Vol.70, No.8, (n.d.), pp.636-
639. 
Claas, F. & Duquesnoy, R. (2008).The polymorphic alloimmune response in clinical 
transplantation. 
Current Opinions in Immunology, Vol.20, No.5, (n.d.), pp.566-567. 
Claas, F. (2004). The acceptable mismatch program as a fast tool for highly sensitized 
patients awaiting cadaveric kidney transplantation: short waiting time and 
excellent graft outcome. Transplantation, Vol.78, No.2, (n.d.),  pp.1046-1056, ISSN 
1046-6673 
Cornell, L.; Smith, R & Colvin, R. (2008). Kidney Transplantation: Mechanisms of Rejection 
and Acceptance. Annual Review of Pathology: Mechanism of Disease, Vol.3, No.12, 
(n.d.), pp.189-220.  
Colvin, R. (2007). Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. 
Journal of the American Society of Nephrology, Vol.18, No.4, (n.d.), pp.1046-1056. 
Danziger-Isakov, L. et al. (2010). Effects of influenza immunization on humoral and cellular 
alloreactivity in humans- Transplantation, Vol.89, No.7, (n.d.), pp.838-844. 
Dau, P. (1995). Immunologic rebound. Journal of clinical apheresis, Vol.10, No.4, (n.d.), pp.210-
217. 
www.intechopen.com
 Kidney Transplantation – New Perspectives 40
Demirhan, B. et al. (1998). Hyperacute allograft rejection mediated by IgM antibodies and a 
negative lymphocyte crossmatch: Report of two cases. Transplantation Proceedings, 
Vol.30, No.3, (n.d.), pp.732-733, ISSN 0041-1345 
Deng, C. et al. (2008). Human leukocyte antigen class II DQ alpha and beta epitopes 
identified from sera of kidney allograft recipients. Transplantation, Vol.86, No.3, 
(n.d.), pp.452-459. 
Di Genova, G. et al. (2006). Vaccination of human subjects expands both specific and 
bystander memory T cells but antibody production remains vaccine specific. Blood, 
Vol.107, No.7, (n.d.), pp.2806-2813. 
Di Genova, G. et al. (2010). Bystander stimulation of activated CD4+ T cells of unrelated 
specificity following a booster vaccination with tetanus toxoid. European Journal of 
Immunology, Vol. 40, No.4, (n.d.), pp.976-985. 
Diaz, J. Cooper, E. & Ochsner, J. (1984). Cold hemagglutination pathophysiology. Evaluation 
and management of patients undergoing cardiac surgery with induced 
hypothermia. Archive of Internal Medicine, Vol.144, No.8, (n.d.), pp.1639-1641, 
Diwan, T. et al. (2011). The impact of proteosome inhibition on alloantibody-producing 
plasma cells in Vivo. Transplantation, Vol.9, No.15, (n.d.), pp.536-541. 
Doherty, P. & Zinkernagel, R. (1997). Rules of engagement: the discovery of MHC 
restriction. Immunology Today, Vol.18, No. 1, (n.d.), pp.14-17. 
Doxiadis, I.; Duquesnoy, R. & Claas, F. (2005). Extending options for highly sensitized 
patients to receive a suitable kidney graft. Curr Opin Immunol, Vol.17, No.5, (n.d.), 
pp.536-540. 
Dunn, T. et al. (2010). Impact of Flow XM Results on Kidney Transplant Outcomes for 
Recipients with Donor Specific Antibody (DSA). Lancet, Vol. 339, No.8809, (n.d.), 
pp.1566-1570, ISSN 102361600-6135 
Duquesnoy, R. (2002). HLAMatchmaker: A molecularly based algorithm for 
histocompatibility determination. I. Description of the algorithm. Human 
Immunology, Vol.63, No.5, (n.d.), pp.339-352, ISSN 0198-8859 
Duquesnoy, R. & Claas, F. (2005). Is the application of HLAMatchmaker relevant in kidney 
transplantation? Transplantation, Vol.79, No.2, (n.d.), pp. 250-251 
Duquesnoy, R. et al. (2005). HLAMatchmaker-based analysis of human monoclonal 
antibody reactivity demonstrates the importance of an additional contact site for 
specific recognition of triplet-defined epitopes. Human Immunology, Vol.66, No.7, 
(n.d.), pp.749-761 
Duquesnoy, R. (2006). A structurally based approach to determine HLA compatibility at the 
humoral immune level. Human Immunology, Vol.67, No.11, (n.d.), pp. 847-862 
Duquesnoy, R.  (2007). ''Match and treat'': an effective strategy for transplanting highly 
sensitized pediatric transplant candidates? Pediatric Transplantation, Vol.11, No.1, 
(n.d.), pp.3-4, 
Duquesnoy, R. & Claas, F. (2007). 14th International HLA and Immunogenetics Workshop: 
report on the structural basis of HLA compatibility. Tissue Antigens, Vol.69, Suppl. 
1, (n.d.), pp.180-184, 
Duquesnoy, R. & Askar, M. (2007). HLAMatchmaker: a molecularly based algorithm for 
histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and 
HLA-DP. Human Immunology, Vol.68, No.1, (n.d.), pp.12-25. 
www.intechopen.com
 Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney Transplantation 41 
Duquesnoy, R. (2008). Clinical usefulness of HLAMatchmaker in HLA epitope matching for 
organ transplantation. Current Opinions in Immunology, Vol.20, No.5, (n.d.), pp.594-
601. 
Duquesnoy, R. (2008). Human leukocyte antigen class II antibodies and transplant outcome. 
Transplantation, Vol.86, No.5, (n.d.), pp.638-640, 
Duquesnoy, R.  (2008). Structural epitope matching for HLA-alloimmunized 
thrombocytopenic patients: a new strategy to provide more effective platelet 
transfusion support? Transfusion, Vol.48, No.2, (n.d.), pp.221-227 
Duquesnoy, R. (2008). Retransplant candidates have donor-specific antibodies that react 
with structurally defined HLA-DR, DQ, DP epitopes. Transplant Immunology, 
Vol.18, No.4, (n.d.), pp.352-360 
Duquesnoy, R. (2008). Structurally based epitope analysis of major histocompatibility 
complex class I-related chain A (MICA) antibody specificity patterns. Human 
Immunology,  Vol.69, No.12, (n.d.), pp. 826-832 
Duquesnoy, R. & Marrari, M. (2009). Correlations between Terasaki's HLA class I epitopes 
and HLAMatchmaker-defined eplets on HLA-A, -B and -C antigens. Tissue 
Antigens, Vol.74, No.2, (August 2009), pp.117-133 
Duquesnoy, R. & Marrari, M. (2010). Detection of antibodies against HLA-C Epitopes in 
Patients with Rejected Kidney Transplants. Tissue Antigens, Vol.74, No.2, (n.d.), 
pp.23-35. 
Edelman, G. (1970). The covalent structure of a human gamma G-immunoglobulin. XI. 
Functional implications. Biochemistry, Vol.9, No.16, (n.d.), pp.3197-3205. 
El-Awar, N.; Lee, J. & Terasaki, P. (2005). HLA antibody identification with single antigen 
beads compared to conventional methods. Human Immunology, Vol.68, No.3, (n.d.), 
pp.989-999, ISSN 0198-8859 
El-Awar, N.; Cook, D. & Terasaki, P. (2006). HLA class I epitopes: A and B loci. Clinical 
Transplantation, Vol.20, No.1, (n.d.), pp.79-94. 
El-Awar, N.; Lee, J. & Terasaki, P. (2006). HLA class I epitopes I: Detection by eluted 
antibodies from recombinant single-antigen cell lines. Human Immunology, Vol.67, 
No.10, (n.d.), p.105, ISSN 0198-8859 
El-Awar, N. & Terasaki, P. (2007). HLA Class I epitopes: 103 total epitopes to-date including 
the C locus. Human Immunology,Vol.68, Suppl. 1, (n.d.), p.45, ISSN 0198-8859 
El-Awar, N. (2007). Human leukocyte antigen class I epitopes: Update to 103 total epitopes, 
including the C locus. Transplantation, Vol.84, No.4, (n.d.), pp.532-540, ISSN 0041-
1337  
El-Awar, N. et al.  (2009). Epitopes of HLA-A, B, C, DR, DQ, DP and MICA antigens, Clinical 
Transplantation, 
Vol.23, No.3, (n.d.), pp.295-321. 
Everly, J. et al.  (2009). Proteasome inhibition for antibody-mediated rejection. Current 
Opinion in Organ Transplantation,  Vol.14, No.6, (August 2009), pp.662-666, 1087-
2418 
Ferrari-Lacraz, S.; Aubert, V. & Buhler L. (2006). Anti-HLA antibody repertoire after IVIg 
infusion in highly sensitized patients waiting for kidney transplantation. Swiss Med 
Wkly, Vol.136, No.44, (n.d.), pp.696-702. 
www.intechopen.com
 Kidney Transplantation – New Perspectives 42
Ferry, B. et al.  (1997). Anti-cell surface endothelial antibodies in sera from cardiac and 
kidney transplant recipients: association with chronic rejection. Transplant 
Immunology, Vol.5, No.1, (n.d.), pp.17-24. 
Fidler, M. et al. (2004). Histologic findings of antibody-mediated rejection in ABO blood-
group-incompatible living-donor kidney transplantation. American Journal of 
Transplantation, Vol.4, No.1, (n.d.), pp.101-107. 
Forman, J. et al. (2004). Significance of anticardiolipin antibodies on short and long term 
allograft survival and function following kidney transplantation. American Journal 
of Transplantation, Vol.4, No.11, (n.d.), pp.1786-1791, ISSN 1600-6135 
Fredrich, R. et al. (1999). The clinical significance of antibodies to human vascular 
endothelial cells after cardiac transplantation. Transplantation, Vol.67, No.3, (n.d.), 
pp.385-391. 
Fuggle, S. et al. (1983). Localization of major histocompatibility complex (HLA-ABC and 
DR) antigens in 46 kidneys. Transplantation, Vol.35, No.4, (n.d.), pp.385-390 
Fuggle, S. & Martin, S. (2008). Tools for human leukocyte antigen antibody detection and 
their application to transplanting sensitized patients. Transplantation, Vol.86, No.3, 
(n.d.), pp. 384-390 
Fujita S.; Rosen, C.; Reed, A. 1997Significance of preformed anti-donor antibodies in liver 
transplantation. Transplantation, Vol.63, No.1, (n.d.), pp. 84-88 
Fuller, A. et al. (1999). Repeat donor HLA-DR mismatches in renal transplantation: is the 
increased failure rate caused by noncytotoxic HLA-DR alloantibodies? 
Transplantation, Vol.68, No.4, (n.d.), pp.589-591. 
Fuller, T. & Fuller, A. (1999). The humoral immune response against an HLA class I 
allodeterminant correlates with the HLA-DR phenotype of the responder. 
Transplantation, Vol.68, No.2, (n.d.), pp.173-182. 
Furth, S. et al. (1999). Plasmapheresis, intravenous cytomegalovirus-specific 
immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal 
transplant recipient: a case report. Pediatrics Transplantation, Vol.3, No.2, (n.d.), pp. 
146-149. 
Futagawa, Y. & Terasaki, P. (2006). ABO incompatible kidney transplantation - an analysis 
of UNOS Registry data. Clinical Transplantation, Vol.20, No.1, (n.d.), pp.122-126, 
ISSN 0902-0063 
Gandhi, M.; Ploeger, N. & DeGoey, S. (2010). Positive virtual crossmatch (VXM), negative 
flow crossmatch (FXM): a case of antibody (Abs) to denatured antige (dAg). Human 
Immunology, Vol.71, No.10, Suppl. 1, (n.d.), p. 4 
Garovoy, M.; Rheinschmidt, M. & Bigos M. (1983). Flow cytometry analysis: A high 
technology crossmatch technique facilitating transplantation. Transplantation 
Proceedings, Vol.15, No.5, (n.d.), pp.1939-1941 
Gebel, H. & Bray, R. (2000). Sensitization and sensitivity: defining the unsensitized patient. 
Transplantation, Vol.69, No.7, pp.1370-1374. 
Gebel, H. et al. (2002). Conundrums with FlowPRA beads. Clinical Transplantation, Vol.16, 
Suppl. 7, (n.d.), pp.24-29, 
Gebel, H.; Bray, R. & Nickerson, P. (2003). Pre-transplant assessment of donor-reactive, 
HLA-specific antibodies in renal transplantation: contraindication vs. risk. American 
Journal of Transplantation, Vol.3, No.12, (n.d.), pp.1488-1500 
www.intechopen.com
 Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney Transplantation 43 
Gebel, H. et al. (2009). Donor-reactive HLA antibodies in renal allograft recipients: 
considerations, complications, and conundrums. Human Immunology, Vol.70, No.8, 
(n.d.), pp.610-617. 
Gebel, H. & Bray, R. (2010). The evolution and clinical impact of Human Leukocyte Antigen 
technology. Current Opinions in Nephrology and Hypertension, Vol.19, No.6, (n.d.), 
pp.598-602, ISSN 1062-4821 
Gebel H. & Halloran, P. (2010). Making Sense of Desensitization. American Journal of 
Transplantation, Vol.10, No.3, (n.d.), pp.443-444, ISSN 1600-6135 
Georgescu, D.; Ferrari-Lacraz, S. & Villard, J. (2007). Anti-HLA antibody detection and 
rejection in kidney transplantation: impact of the new technologies. Reviews 
Medicale Suisse, Vol.25, No.3, (n.d.), pp.1064-1069. 
Ghasemian, S. et al. (1998). Dec- Hyperacute rejection from antibody against class II HLA 
antigens- 12- 6, Clinical Transplantation, Vol.12, No.6, (n.d.), pp.569-571. 
Gloor, J. et al. (2004). Persistence of low levels of alloantibody after desensitization in 
crossmatch-positive living-donor kidney transplantation. Transplantation, Vol.78, 
No.2, (n.d.), pp.221-227, ISSN 0041-1337 
Gloor, J. et al. (2004). Kidney transplantation following administration of high dose 
intravenous immunoglobulin in patients with positive flow cytometric/negative 
enhanced cytotoxicity crossmatch. American Journal of Transplantation, Vol.4, Suppl. 
8, (n.d.), p.256, ISSN 1600-6135 
Gloor, J. (2006). Histologic findings one year after positive crossmatch or ABO blood group 
incompatible living donor kidney transplantation. American Journal of 
Transplantation, Vol.6, No.8, (n.d.), pp.1841-1847, ISSN 1600-6135 
Gloor, J. & Stegall, M. (2007).ABO incompatible kidney transplantation. Current Opinions in 
Nephrology and Hypertension, Vol.16, No.6, (November 2007), (n.d.), pp.529-534  
Glotz, D. (2004). Intravenous immunoglobulins and transplantation for patients with anti-
HLA antibodies. Transplant International, Vol.17, No.1, (n.d.), pp.1-8, ISSN 0934-0874 
Goral, S. et al. (2008). Preformed donor-directed anti-HLA-DP antibodies may be an 
impediment to successful kidney transplantation. Nephrology Dialysis and 
Transplantation, Vol.23, No.1, (n.d.), pp.390-392, ISSN 0931-0509 
Graff, R. et al. (2009). The role of positive flow cytometry crossmatch in late renal allograft 
loss. Human Immunology, Vol.70, No.7, (n.d.), pp.502-505. 
Grandtnerova, B. et al. (1995). Treatment of Acute Humoral Rejection in Kidney-
Transplantation with Plasmapheresis. Transplantation Proceedings, Vol.27, No.1, 
(n.d.), pp.934-935. 
Grandtnerova, B. (2008). Hyperacute rejection of living related kidney grafts caused by 
endothelial cell-specific antibodies: Case reports. Transplantation Proceedings, Vol.40, 
No.7, (n.d.), pp.2422-2424. 
Guardiola, J. & Maffei, A. (1993). Control of MHC class II gene expression in autoimmune, 
infectious, and neoplastic diseases. Critical Reviews in Immunology, Vol.13, No.4, 
(n.d.), pp.247-268. 
Han, F. et al. (2009). Pre-transplant serum concentrations of anti-endothelial cell antibody in 
panel reactive antibody negative renal recipients and its impact on acute rejection. 
Clinical Chemistry and Laboratory Medicine, Vol.47, No.10, (n.d.), pp.1265-1269. 
www.intechopen.com
 Kidney Transplantation – New Perspectives 44
Haririan, A. et al. (2009). The Impact of C4d Pattern and Donor-Specific Antibody on Graft 
Survival in Recipients Requiring Indication Renal Allograft Biopsy. American 
Journal of Transplantation, Vol.9, No.12, (n.d.), pp.2758-2767, ISSN 1600-6135 
Haririan, A. et al.(2009). Positive Cross-Match Living Donor Kidney Transplantation: 
Longer-Term Outcomes Editorial Comment. Journal of Urology, Vol.182, No.3, (n.d.), 
p.1138, ISSN 0022-5347 
Harmer, A. et al. (1993). Highly Sensitive, Rapid Screening Method for the Detection of 
Antibodies Directed Against Hla Class-I and Class-Ii Antigens. Transplant 
International, Vol. 6, No.5, (n.d.), pp.277-280, ISSN 0934-0874. 
Harris, E. & Pierangeli, S. (2000). Equivocal' antiphospholipid syndrome. Journal of 
Autoimmunity, Vol. 15, No.2, (n.d.), pp. 81-85, ISSN 0896-8411 
Hart, D. (1981). Localization of HLA-ABC and DR antigens in human kidney. 
Transplantation, Vol.31, No.6, (n.d.), pp.428-433, 
Higgins, R. (2009). Rises and falls in donor-specific and third-party HLA antibody levels 
after antibody incompatible transplantation. Transplantation, Vol.87, No.6, (n.d.), 
pp.882-888. 
Hill, N. & Sarvetnick, N. (2002). Cytokines: promoters and dampeners of autoimmunity. 
Current Opinion in Immunology, Vol.14, No.6, (n.d.), pp.791-797, ISSN 0952-7915 
Horsburgh, T.; Martin, S. & Robson, A. (2000). The application of flow cytometry to 
histocompatibility testing. Transplant Immunology, Vol.8, No.1, (n.d.), pp.3-15, ISSN 
0966-3274 
Husby, G. et al. (1989). Cross-reactive epitope with Klebsiella pneumoniae nitrogenase in 
articular tissue of HLA-B27+ patients with ankylosing spondylitis. Arthritis Rheum, 
Vol.32, No.4, (n. d.), pp.437-445. 
Issitt, P. & Issitt, C. (1979). Applied Blood Group Serology (2 nd edition), Spectra Biologicals, 
ISBN 7434546, Oxnard, CA. 
Izzat, M.;  Rajesh, P. & Smith, G. (1993). Use of retrograde cold crystalloid cardioplegia in a 
patient with unexpected cold agglutination. Annals of Thoracic Surgery, Vol.56, No.6, 
(n.d.), pp.1395-1397 
Jiang, S. & Lechler, R. (2003). Regulatory T cells in the control of transplantation tolerance 
and autoimmunity. American Journal of  Transplantation, Vol.3, No.5, (n.d.), pp.516-
524. 
Jin, Y. et al. (2002). Ligation of HLA class I molecules on endothelial cells induces 
phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent 
manner. Journal of Immunology, Vol.168, No.11, (n.d.), pp.5415-5423, 
Johnson, A. et al. (1986). Recognition of an HLA-DPw1 specific alloantiserum raised by 
planned Immunization. Human Immunology, Vol.17, No.2, pp.21-29. 
Jordan, S.; Cunningham-Rundles, C. & McEwan R. (2003). Utility of Intravenous immune 
globulin in Kidney Transplantatio: Efficacy, Safety, and Cost Implications. American 
Journal of Transplantation, Vol.3, No.12, (n.d.), pp.653-664. 
Jordan, S. et al. (2004). Evaluation of intravenous immunoglobulin as are agent to lower 
allosensitization and improve transplantation in highly sensitized adult patients 
with end-stage renal disease: Report of the NIHIG02 trial. Journal of the American 
Society of Nephrology, Vol.15, No.12, (n.d.), pp.3256-3262, ISSN 1046-6673. 
www.intechopen.com
 Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney Transplantation 45 
Jordan, S. et al. (2006). Desensitization therapy with intravenous immunoglobulin (IVIG): 
applications in solid organ transplantation. Transactions of the American clinical and 
climatological association, Vol.117, No.8, (n.d.), pp.199-211 
Jordan, S.; Peng, A. & Vo A. (2009). Therapeutiv Strategies in Management of the Highly 
HLA-Sensitized and ABO-incompatible Transplant Recipients, In:  Humoral 
Immunity in Kidney Transplanation. What clinicians Need to know, G. Remuzzi, S. 
Chiaramonte, N. Perico, C. Ronco, (Eds), pp. 13-26, Karger, ISBN 1021-9749, Basel. 
Kahwaji, J. et al. (2009). Acute Hemolysis After High-Dose Intravenous Immunoglobulin 
Therapy in Highly HLA Sensitized Patients. Clinical Journal of the American Society of 
Nephrology, Vol.4, No.12, (n.d.), pp.1993-1997, ISSN 1555-9041 
Kalil, J. (1989). Humoral Rejection in 2 HLA Identical Living Related Donor Kidney-
Transplants. Transplantation Proceedings, Vol.21, No.1, (n.d.), pp.711-713, ISSN 0041-
1345 
Kamoun M. et al. (2006). A successful kidney transplant in a patient  re-grafted across an 
incompatible crossmatch secondary to anti-HLA-DP antibodies using intensive 
immunosuppression. Transplantation, Vol.82, No.1, (n.d.), pp.779-1018, 
Kazatchkine, M. & Kaveri, S. (2001). Advances in immunology: Immunomodulation of 
autoimmune and inflammatory diseases with intravenous immune globulin. New 
England Journal of Medicine, Vol.345, No.10, (n.d.), pp.747-755, ISSN 0028-4793 
Kennedy, R. et al. (2010). Effect of human leukocyte antigen homozygosity on rubella 
vaccine-induced humoral and cell-mediated immune responses. Human 
Immunology, Vol.71, No.2, (n.d.), pp.128-135. 
Kerman, R. et al. (1996). Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in 
pretransplant sera with renal allograft rejection. Clinical Transplantation, Vol. 62, 
No.2, (n.d.), pp.201-205, ISSN 0041-1337 
Kerman, R.; Orosz, C. & Lorber, M. (1997). Clinical relevance of anti-HLA antibodies pre 
and post transplant. American Journal of Medical Science, Vol.13, No.5, (n.d.), pp.275-
278, ISSN 0002-9629 
Klaesson, S. et al. (1993). Immune modulatory effects of immunoglobulins on cell-mediated 
immune responses in vitro. Scandinavian Journal of Immunology, Vol.38, No.5, (n.d.), 
pp.477-484. 
Knight, R. et al. (1995). Renal allograft thrombosis associated with the antiphospholipid 
antibody syndrome. Transplantation, Vol.60, No.6, (n.d.), pp.614-615. 
Koka, P. et al. (1993).The Role of IgA Anti-HLA Class-I Antibodies in Kidney-Transplant 
Survival. Transplantation, Vol.56, No.1, (n.d.), pp.207-211, ISSN 0041-1337 
Lachmann, N. (2008). Single amino acid mismatches determine immunogenic HLA epitopes. 
Tissue Antigens, Vol.72, No.3, p.253, ISSN 0001-2815 
Laux G.; Mansmann, U.; Deufel, A. 2003A new epitope-based HLA-DPB matching approach 
for cadaver kidney retransplants. Transplantation, Vol.75, No.9, (n.d.), pp.1527-1532, 
ISSN 0041-1337 
Le Bas-Bernardet, S. et al. (2003).  Non-HLA-type endothelial cell reactive alloantibodies in 
pre-transplant sera of kidney recipients trigger apoptosis. American Journal of 
Transplantation, Vol.3, No.2, (n.d.), pp.167-177, ISSN 1600-6135 
Lederer, S. et al. (1996). Early renal graft dysfunction - The role of preformed antibodies to 
DR-typed lymphoblastoid cell lines. Transplantation, Vol.61, No.2, (n.d.), pp.313-
319, ISSN 0041-1337 
www.intechopen.com
 Kidney Transplantation – New Perspectives 46
Lefaucheur, C. et al. (2009). Clinical relevance of preformed HLA donor-specific antibodies 
in kidney transplantation. Contributive Nephrology, Vol.162, No.1, (n.d.), pp.1-12. 
Lehrich, R. et al. (2005). Intravenous immunoglobulin and plasmapheresis in acute humoral 
rejection: experience in renal allograft transplantation. Human Immunology, Vol.66, 
No.4, pp.350-358. 
Leong H.; Stachnik, J.; Bonk, M.E. (2008). Unlabeled uses of intravenous immune globulin. 
American Journal of Health-System Pharmacy, Vol. 65, No.19, (n.d.), pp.1815-1824, 
ISSN 1079-2082 
Levings, M. & Thomson, A. (2009). Mastering Treg function to promote tolerance. American 
Journal of Transplantation, Vol.9, No.10, (n.d.), pp.2209-2210. 
Lobashevsky, A. et al. (2000). Specificity of preformed alloantibodies causing B cell positive 
flow crossmatch (FCXM) in renal transplantation. Clinical Transplantation, Vol.14, 
No.6, (n.d.), pp.533-542, ISSN 0902-0063 
Lobashevsky, A. et al. (2002). The number of amino acid residues mismatches correlates 
with flow cytometry crossmatching results in high PRA renal patients. Human 
Immunology, Vol.63, No.5, pp.364-374, ISSN 0198-8859 
Lobashevsky, A. et al. (2009). Comparative evaluation of tepnel lifecodes solid phase and 
lymphocyte cross match assay. Tissue Antigens, Vol.73, No.5, (n.d.), p.119 
Lobashevsky, A. et al. (2009). Effect of desensitization in solid organ transplant recipients 
depends on some cytokines genes polymorphism. Transplant Immunology, Vol.21, 
No.3, (n.d.), pp.169-178. 
Lobashevsky, A. & Higgins N. (2009). Predictive values (PV) of class I and class II antibodies 
(Ab) detected by luminex. Human Immunology, Vol.70, Suppl. 1, (n.d.), p.32. 
Lobashevsky, A. et al. (2010). Subtypes of immunoglobulin (Ig)-G antibodies against donor 
Class II HLA and cross-match results in three kidney transplant candidates. Vol.23, 
No.77, (n.d.), pp.81-85, ISSN 0966-3274 
Lobashevsky, A. et al. (2011). Allelic mismatch at HLA-DRB3 locus resulted in production of 
broad specrtrum of alloantibodies. Tissue antigens,Vol.77, No.5, (May 2011), p.377. 
Lobo, P. et al. (1995).Evidence Demonstrating Poor Kidney Graft-Survival When Acute 
Rejections Are Associated with IgG Donor-Specific Lymphocytotoxin. 
Transplantation, Vol.59, No.3, (n.d.), pp.357-360, 0041-1337 
Lobo, P.;  Sturgill, B. & Bolton, W. (1984). Cold-reactive alloantibodies and allograft 
malfunction occurring immediately posttransplant. Transplantation, Vol.37, No.1, 
(n.d.), pp.76-81. 
Lomago, J. et al. (2010). How did a patient who types for HLA-B*4403 develop antibodies 
that react with HLA-B*4402? Human Immunology, Vol.71, No.2, (n.d.), pp.176-178. 
Lucchiari, N. et al. (2000). Antibodies fluted from acutely rejected renal allografts bind to 
and activate human endothelial cells Human Immunology, Vol.61, No.5, (n.d.), 
pp.518-527, 0198-8859 
Lutz, H. et al. (2004). Intravenously applied IgG stimulates complement attenuation in a 
complement-dependent auto-immune disease at the amplifying C3 convertase 
level. Blood, Vol. 103, No.11, (n.d.), pp.465-472. 
Marrari, M. & Duquesnoy, R. (2009). Correlations between Terasaki's HLA class II epitopes 
and HLAMatchmaker-defined eplets on HLA-DR and -DQ antigens. Tissue 
Antigens, Vol.74, No.2, (August 2009), pp.34-46 
www.intechopen.com
 Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney Transplantation 47 
Marrari, M. & Duquesnoy, R. (2009). Why can sensitization by an HLA-DR2 mismatch lead 
to antibodies that react also with HLA-DR1? Human Immunology, Vol.70, No.6, 
(n.d.), pp.403-409. 
Marrari, M. & Duquesnoy, R.J. (2010). Detection of donor-specific HLA antibodies before 
and after removal of a rejected kidney transplant. Transplant Immunology, Vol.22, 
No.3-4, (n.d.), pp.105-109, ISSN 0966-3274 
Marrari, M. et al. (2010). Human Monoclonal Antibody Reactivity With Human Leukocyte 
Antigen Class I Epitopes Defined by Pairs of Mismatched Eplets and Self-Eplets. 
Transplantation, Vol.90, No.12, (December 2010), pp.1468-1472, ISSN 0041-1337 
Marsh, S.; Parham, P. & Barber L. (2000). The HLA Facts Book, Academic Press, ISBN 
0125450257, San Diego, CA  
Martin, L. et al. (2003). Detection of donor-specific anti-HLA antibodies with flow cytometry 
in eluates and sera from renal transplant recipients with chronic allograft 
nephropathy. Transplantation, Vol. 76, No.2, (July 2003), pp.395-400, ISSN 0041-1337 
Matas, A. et al. (2000). Immunologic and nonimmunologic factors - Different risks for 
cadaver and living donor transplantation. Transplantation, Vol.69, No.1, (n.d.), 
pp.54-58, ISSN 0041-1337 
McCalmon, R. et al. (1997). IgM antibodies in renal transplantation. Clinical Transplantation, 
Vol.11, No.6, pp.558-564, ISSN 0902-0063 
McKenna, R. Takemoto, S. & Terasaki, P. (2000). Anti-HLA antibodies after solid organ 
transplantation. Transplantation, Vol.69, No.3, (n.d.), pp.319-326, ISSN 0041-1337 
Meroni, P.; Raschi, E. & Testoni, C. (2002). Endothelium as a target for anti-phospholipid 
antibodies and for therapeutic intervention. Autoimmunity Reviews, Vol.1, No.1, 
(n.d.), pp.55-60, 
Mitchell, B. (2003). The proteasome - An emerging therapeutic target in cancer. New England 
Journal of Medicine, Vol.348, No.26, (n.d.), pp.2597-2598, ISSN 0028-4793 
Mizutani, K. et al. (2005).Identical kidney transplant recipients who reject grafts have high 
incidences of antibodies to endothelial cells and MICA. Human Immunology, Vol.6, 
No.6, (n.d.), p86, ISSN 0198-8859. 
Mizutani, K. et al. (2006). Frequency of MIC antibody in rejected renal transplant patients 
without HLA antibody. Human Immunology, Vol.67, No.3, (n.d.), pp.223-229, ISSN 
0198-8859 
Montgomery, R. & Locke, J. (2007). ABO-incompatible transplantation: less may be more. 
Transplantation, Vol.84, No.12, (Supp.l), (n.d.), pp.8-9. 
Moraes, J. & Stastny P. (1976). Eight groups of human endothelial cell alloantigens. Tissue 
Antigens, Vol.8, No.4, (n.d.), pp.273-276. 
Morales-Buenrostro, L. et al. (2008). "Natural" human leukocyte antigen antibodies found in 
nonalloimmunized healthy males. Transplantation, Vol.86, No. 8, (October 2007), 
pp.1111-1115, 
Muczynski, K. et al. (2003). Normal human kidney HLA-DR-expressing renal microvascular 
endothelial cells: characterization, isolation, and regulation of MHC class II 
expression. Journal of American Society for Nephrology, Vol.14, No.5, (n.d.), pp.1336-
1348. 
Mujtaba, M. et al. (2011). The strength of donor-specific antibody is a more reliable predictor 
of antibody-mediated rejection than flow cytometry crossmatch analysis in 
www.intechopen.com
 Kidney Transplantation – New Perspectives 48
desensitized kidney recipients. Clinical Transplantation, Vol. 25, No.1, (n.d.), pp.96-
102. 
Müller, C. et al.(1989).Expression of HLA-DQ, -DR, and -DP antigens in normal kidney and 
glomerunephritis. Kidney International, Vol.35, No.1, pp.116-124 
Mytilineos, J.; Deufel, A. & Opelz, G. (1997). Clinical relevance of HLA-DPB locus matching 
for cadaver kidney retransplants - A report of the Collaborative Transplant Study. 
Transplantation, Vol.63, No.9, (n.d.), pp.1351-1354, ISSN 0041-1337 
Nelson, P. (1998). Ten-year experience in transplantation of A2 kidneys into B and O 
recipients. Transplantation, Vol.65, No.2, (n.d.), pp.55-60. 
Ogasawara, M.; Kono, D. & Yu, D. (1986). Mimicry of human histocompatibility HLA-B27 
antigens by Klebsiella pneumoniae. Infectious Immunology, Vol.51, No.3, (n.d.), pp.901-
908. 
Opelz, G. (2005). Non-HLA transplantation immunity revealed by lymphocytotoxic 
antibodies. Lancet, 
Vol.365, No.9470, (n.d.), pp.1570-1576, ISSN 0140-6736 
Ozawa, M. et al. (2006). Detection of MICA antibodies and epitope analysis using Luminex 
MICA single antigen bead. Human Immunology, Vol.67, No.10, (n.d.), p.52, ISSN 
0198-8859 
Patel, A. et al. (2007). Renal transplantation in patients with pre-transplant donor-
specificantibodies and negative flow cytometry crossmatches. American Journal of 
Transplantation, Vol. 7, No.10, (n.d.), pp.2371-2377. 
Pei, R. et al. (2003). Single human leukocyte antigen flow cytometry beads for accurate 
identification of human leukocyte antigen antibody specificities. Transplantation, 
Vol.75, No.1, (n.d.), pp.43-49, ISSN 0041-1337 
Perrey, C. et al. (1998). An association between antibodies specific for endothelial cells and 
renal transplant failure. Transplant Immunology, Vol.6, No.2, (n.d.), pp.101-106, ISSN 
0966-3274 
Perry, D. et al. (2009). Proteasome Inhibition Causes Apoptosis of Normal Human Plasma 
Cells Preventing Alloantibody Production. American Journal of Transplantation, 
Vol.9, No.1, (n.d.), pp.201-209, ISSN 1600-6135 
Peters, K. et al. (2004). Functional significance of Tie2 signaling in the adult vasculature. 
Recent Progress in Hormone Research, Vol.59, No. 6, (n.d.), pp.51-71, 
Piazza, A. et al. (2006). Anti-DP antibodies and graft failure in kidney transplantation. 
American Journal of Transplantation, Vol.6, No.7, (n.d.), pp.473-476 
Pierangeli, S. & Harris, N. (2003). Diagnosis of Antiphopholipid Syndrome. Clinical 
Immunology, Vol.3, No.1, (n.d.), pp.13-17. 
Pober, J. et al. (1997). Vascular cells have limited capacities to activate and differentiate T 
cells: implications for transplant vascular sclerosis. Transplant Immunology, Vol.5, 
No.4, (n.d.), pp.251-254. 
Pober, J. et al. (1996). Can graft endothelial, cells initiate a host anti-graft immune response? 
Transplantation,Vol.61, No.3, (n.d.), pp.343-349, ISSN 0041-1337 
Poli, F.; Cardillo, M. & Scalamogna, M. (2009). Clinical relevance of human leukocyte 
antigen antibodies in kidney transplantation from deceased donors: the North Italy 
Transplant program approach. Human Immunology, Vol.70, No.8, (n.d.), pp.631-635. 
Porter, R. (1970). The structure and combining specificity of antibodies. Biochemical Society 
Symposia, Vol.30, (n.d.), pp.89-98. 
www.intechopen.com
 Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney Transplantation 49 
Qasi, Y.; Hermes, M. & Cicciarelli, J. (2006). Graft loss in three patients with donor-specific 
antibody (DSA). In: Clinical transplants, Terasaki, P., pp.541-543, Terasaki 
foundation Laboratory, ISBN 978-1-880318-15-7, Los Angeles, CA. 
Qiu, J. et al. (2005). Detection of antibodies to HLA-DP in renal transplant recipients using 
single antigen beads. Transplantation, Vol.80, No.10, (n.d.), pp.1511-1513, ISSN 0041-
1337 
Racusen, L.; Solwz, K. & Burdick J. (1998). Kidney transplant rejection. Diagnosis and treatment, 
Dekker Inc., 3d edition, ISBN 1260-8247-0139-9, Marcel, New York, Bazel, Hong 
Kong. 
Raghavan, R. et al. (2010). Bortezomib in Kidney transplantation. Journal of Transplantation, 
Vol.2010, No.11, (n.d.), pp.1-6 
Rebellato, L. et al. (2006). Antibodies against HLA class I/II and MICA in rejection and at 
graft failure. Human Immunology, Vol.67, No. 10, (n.d.), p.86, ISSN 0198-8859 
Reinsmoen, N. et al.  (2008). Acceptable donor-specific antibody levels allowing for 
successful deceased and living donor kidney transplantation after desensitization 
therapy. Transplantation, 866, (n.d.), pp.820-825, ISSN 0041-1337 
Rifle, G. & Mousson, C. (2003). Donor-derived hematopoietic cells in organ transplantation: 
A major step toward allograft tolerance? Transplantation, Vol.75, No.9, (n.d.), pp.3-7, 
ISSN 0041-1337 
Rivera, R. & Scornik, J. (1986). HLA antigens on red cells. Implications for achieving low 
HLA antigen content in blood transfusions. Transfusion, Vol.26, No.4, (n.d.), pp.375-
381 
Rodey, G. & Fuller, T. (1987). Public epitopes and the antigenic structure of the HLA 
molecules. Critical Reviews in Immunology, Vol.7, No.3, (n.d.), pp.229-267. 
Rodriguez, P. (2000). Detection of alloantibodies against non-HLA antigens in kidney 
transplantation by flow cytometry. Clinical Transplantation, Vol.14, No.5, (n.d.), 
pp.472-478, ISSN 0902-0063 
Roelcke, D. (1974). Cold agglutination. Antibodies and antigens. Clinical Immunology and 
Immunopathology, Vol.2, No.2, (n.d.), pp.266-280, 
Roelcke, D. (1989). Cold agglutination. Transfusion Medicine Reviews, Vol.3, No.2, (n.d.), 
pp.140-166, 
Rogers, N. et al. (2011). Desensitization for renal transplantation: depletion of donor-specific 
anti-HLA antibodies, preservation of memory antibodies, and clinical risks. 
Transplant International, Vol.24, No.1, (n.d.), pp.21-29, ISSN 0934-0874 
Rosenberg WMC; Bushell A; Higgins R. 1992Isolated HLA-DP mismatches between donors 
and recipients Do Not Influence the function or outcome of renal transplants. 
Human Immunology, Vol.35, No.9, (n.d.), pp.5-9, 
Ruschak, A. et al. (2010). The proteasome antechamber maintains substrates in an unfolded 
state. Nature, Vol.467, No.7317, (n.d.), pp. 868-872, ISSN 0028-0836 
Rydberg, L.; Skogsberg, U. & Molne, J. (2007). ABO antigen expression in graft tissue: is 
titration against donor erythrocytes relevant? Transplantation, Vol.84, No.12, (Supp. 
l), (n.d.), pp. 10-12.  
Saw, C.; Bray, R. & Gebel, H. (2008). Cytotoxicity and antibody binding by flow cytometry: a 
single assay to simultaneously assess two parameters. Cytometry B. Clinical 
Cytometry, Vol.74, No.5, (n.d.), pp.287-294. 
www.intechopen.com
 Kidney Transplantation – New Perspectives 50
Sberro-Soussan, R. et al. (2010). Bortezomib as the Sole Post-Renal Transplantation 
Desensitization Agent Does Not Decrease Donor-Specific Anti-HLA Antibodies. 
American Journal of Transplantation, Vol.10, No.3, (n.d.), pp.681-686, ISSN 1600-6135 
Schonemann, C. et al. (1998). HLA class I and class II antibodies - Monitoring before and 
after kidney transplantation and their clinical relevance. Transplantation, Vol.65, 
No.11, (n.d.), pp.1519-1523, ISSN 0041-1337 
Scornik, J. et al. (1989). Role of anti-donor antibodies in bone marrow transplant rejection: 
evaluation by flow cytometry and effect of plasma exchanges. Transplant Proc, 
Vol.21, No.1, Pt. 3, (n.d.), pp.2974-2975, ISSN 0041-1345 
Scornik, J. et al. (1992). Hyperacute and acute kidney graft rejection due to antibodies 
against B cells. Transplantation, Vol.54, No.1, (n.d.), pp.61-64. 
Scornik, J. et al. (1997). Multicenter evaluation of the flow cytometry T-cell crossmatch: 
results from the American Society of Histocompatibility and Immunogenetics-
College of American Pathologists proficiency testing program. Transplantation, 
Vol.63, No.10, (n.d.), pp.1440-1445, 
Shenton, B. et al. (1995). The value of flow cytometric crossmatching in lung transplantation: 
relevance of pretransplant antibodies to lung epithelial cells. Transplant Proc, 
Vol.27, No.1, (n.d.), pp.1295-1297, ISSN 0041-1345. 
Shimmura, H. et al. (2004). Impact of positive PRA on the results of ABO-incompatible 
kidney transplantation. Transplant Proceedings, Vol.36, No. 7, (September 2004), 
(n.d.), pp.2169-2171  
Shroyer, T. et al.  (1995). A Rapid Flow-Cytometry Assay for HLA Antibody Detection Using 
A Pooled Cell Panel Covering 14 Serological Cross-Reacting Groups. 
Transplantation, Vol.59, No.4, (n.d.), pp.626-630, ISSN 0041-1337 
Smith, J. et al. (2007). C4d fixing, luminex binding antibodies - a new tool for prediction of 
graft failure after heart transplantation. American Journal of Transplantation, Vol.7, 
No.12, pp.2809-2815.  
Smith, J. & Rose M. (2009). Transplantation Immunology: methods and Protocols. In: 
Detection and Clinical Relevance of Antibodies After Transplantation, Hornick, P. & 
Rose, M., pp.227-245, Humana Press Inc., Totowa, NJ 
Sonnenday, C. et al. (2004). Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 
allow ABO-incompatible renal transplantation without splenectomy. American 
Journal of Transplantation, Vol.4, No.8, (n.d.), pp.1315-1322, ISSN 1600-6135 
Squifflet, J. et al. (2004). Lessons learned from ABO-incompatible living donor kidney 
transplantation: 20 years later. Experimental Clinical Transplantation, Vol.2, No.1, 
(n.d.), pp.208-213. 
Stasi, R. et al. (2008). Analysis of regulatory T-cell changes in patients with idiopathic 
thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. 
Blood, Vol.112, No.4, (n.d.), pp.1147-1150, ISSN 0006-4971 
Stastny, P. et al. (2006). Four short projects about antibodies, soluble CD30, and organ 
transplant rejection. In: Clinical transplants 2006, Terasaki, P., pp.337-342, Terasaki 
foundation Laboratory, ISBN 978-1-880318-15-7,Los Angeles, CA 
Stastny, P. et al. (2009). Role of immunoglobulin (Ig)-G and IgM antibodies against donor 
human leukocyte antigens in organ transplant recipients. Human Immunology, 
Vol.70, No.8, (n.d.), pp.600-604. 
www.intechopen.com
 Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney Transplantation 51 
Stegall, M.; Dean, P. & Gloor, J. (2009). Mechanisms of alloantibody production in sensitized 
renal allograft recipients- Am J Transplantation, Vol.9, No.5, (n.d.), pp.998-1005. 
Sturgill, B.; Lobo, P. & Bolton, W. (1984).Cold-reacting IgM antibody-induced renal allograft 
failure. Similarity to hyperacute rejection. Nephron, Vol.36, No.2, (n.d.), pp.125-127 
Sugiyama, K. et al. (2005). Reversibility from delayed hyperacute rejection in ABO-
incompatible renal transplantation: histopathological findings of renal allograft 
biopsy. Transplantation Proceedings, Vol.37, No.2, (n.d.), pp.701-704. 
Sumitran-Holgersson, S. (2001). HLA-specific alloantibodies and renal graft outcome. 
Nephrology Dialysis and Transplantation, Vol.16, No.5, (n.d.), pp.897-904. 
Sumitran-Karuppan, S. et al. (1997). Hyperacute rejections of two consecutive renal 
allografts and early loss of the third transplant caused by non-HLA antibodies 
specific for endothelial cells. Transplant Immunology, Vol.5, No.4, (n.d.), pp.321-327, 
ISSN 0966-3274 
Supon P. et al. (2001). Prevalence of donor-specific anti-HLA antibodies during episodes of 
renal allograft rejection. Transplantation, Vol.7, No.14, (n.d.), pp.577-580, ISSN 0041-
1337 
Susal, C. & Opelz, G. (2002). Kidney graft failure and presensitization against HLA class I 
and class II antigens. Transplantation, Vol.73, No.8, (n.d.), pp.1269-1273. 
Tabata, T. et al. (2003). Accommodation after lung xenografting from hamster to rat. 
Transplantation, Vol.75, No.5, (n.d.), pp.607-612 
Takemoto, S. (1995). Sensitization and Crossmatch. In: Clinical Transplants, Terasaki, P., 
pp.417-432. Astellas Pharma US, Inc.,  ISBN 0890-9016, Los Angeles, CA 
Takemoto, S. et al. (2004). HLA matching for kidney transplantation. Human Immunology, 
Vol.65, No.12, (n.d.), pp.1489-1505, 
Tanabe, K. (2007). Japanese experience of ABO-incompatible living kidney transplantation. 
Transplantation, Vol.84, No.12, (Suppl. 1), (n.d.), pp. 4-7. 
Terasaki, P. (2003). Humoral theory of transplantation. American Journal of Transplantation, 
Vol.3, No.6, (n.d.), pp.665-673. 
Terasaki, P. & Cai, J. (2008). Human leukocyte antigen antibodies and chronic rejection: from 
association to causation. Transplantation, Vol.86, No.3, (n.d.), pp.377-383. 
Terasaki, P. & Cai, J. (2005). Humoral theory of transplantation: further evidence. Current 
Opinions in Immunology, 
Vol.17, No.5, (n.d.), pp.541-545, ISSN 0952-7915 
Thielke, J. et al. (2005). Highly successful living donor kidney transplantation after 
conversion to negative of a previously positive flow-cytometry cross-match by 
pretransplant plasmapheresis. Transplantation Proceedings, Vol.37, No.2, (n.d.), 
pp.643-644. 
Tobian, A. et al. (2009). Therapeutic plasma exchange reduces ABO titers to permit ABO-
incompatible renal transplantation. Transfusion, Vol.49, No.6, (n.d.), pp.1248-1254, 
ISSN 0041-1132 
Toyoda, M. (2004). Modulation of anti-class I, anti-class II and anti-endothelial cell 
antibodies by intravenous gammaglobulin (IVIG) improves transplant rates and 
reduces allograft rejection in highly-sensitized patients. American Journal of 
Transplantation, Vol.4, No.10, (n.d.), pp.550-556, ISSN 1600-6135 
Toyofuku, A. et al. (2006). Natural killer T-cells participate in rejection of islet allografts in 
the liver of mice. Diabetes, Vol.55, No.1, (n.d.), pp.34-39. 
www.intechopen.com
 Kidney Transplantation – New Perspectives 52
Tsang J. et al. (2007). Generation of CD4+CD25+ regulatory T cells with indirect 
alloresponses by T cell receptor gene transfer: A novel therapeutic agent for the 
induction of transplantation tolerance. American Journal of Transplantation, Vol.7, 
No.9, (n.d.), pp.172-180. ISSN 1600-6135 
Tyden, G. et al. (2005). ABO incompatible kidney transplantations without splenectomy, 
using antigen-specific immunoadsorption and rituximab. Transplantation 
Proceedings, Vol.37, No.8, (n.d.), pp.145-148, ISSN 1600-6135 
Tyden, G. (2007). The European experience. Transplantation, Vol.84, No.12, (n.d.), pp.1-3. 
Tyden, G. (2010). ABO-incompatible kidney transplantation and rituximab. Transplantation, 
Vol.74, No.8, pp.11-7 
Vaidya, S. et al. (1998). Relative risk of post-transplant renal thrombosis in patients with 
antiphospholipid antibodies. Clinical Transplantation, Vol.12, No.5, (n.d.), pp.439-
444. 
Vaidya, S. et al. (2001). Pronase improves detection of HLA antibodies in flow crossmatches. 
Transplantation Proceedings, Vol.33, No.1-2, (n.d.), pp.473-474, ISSN 0041-1345 
Vaidya, S. et al. (2007). DP reactive antibody in a zero mismatch renal transplant pair. 
Human Immunology, 
Vol.68, No.11, (n.d.), pp.947-949 
Valli, P. et al. (2009). Changes of circulating antibody levels induced by ABO antibody 
adsorption for ABO-incompatible kidney transplantation. American Journal of 
Transplantation, Vol.9, No.5, (n.d.), pp.1072-1080. 
Vanderwoude, F. et al. (1995). Tissue Antigens in Tubulointerstitial and Vascular Rejection. 
Kidney International, Vol.48, No. 4, (n.d.), pp.11-13, ISSN 0085-2538 
Vasilescu, E. et al. (2004). Anti-HLA antibodies in heart transplantation. Transplant  
Immunology, Vol.12, No.2, (n.d.), pp.177-183. 
Vella, J. (2004). Significance of anticardiolipin antibodies on short- and long-term allograft 
survival and function following kidney transplantation. American Journal of 
Transplantation, Vol.4, No.11, (n.d.), pp.1731-1732, ISSN 1600-6135 
Vincent, R. et al. (1996). Quantitative analysis of the expression of the HLA-DRB genes at the 
transcriptional level by competitive polymerase chain reaction. Journal of 
Immunology, Vol.156, No.2, (n.d.), pp.603-610, ISSN 0022-1767 
Vo, A. et al. (2008). Rituximab and intravenous immune globulin for desensitization during 
renal transplantation. New England Journal of Medicine, Vol.359, No.3, pp.242-251, 
ISSN 0028-4793 
Vo, A. et al. (2010). Use of Intravenous Immune Globulin and Rituximab for Desensitization 
of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation. 
Transplantation, Vol.89, No.9, (n.d.), pp.1095-1102, ISSN 0041-1337 
Wagenknecht, D. et al. (2000). Risk of early renal allograft failure is increased for patients 
with antiphospholipid antibodies- Transplant International, Vol.13, Suppl. 1, (n.d.), 
pp.78-81. 
Walsh, R. et al. (2010). Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated 
Renal Allograft Rejection. Transplantation, 893, (n.d.), pp.277-284, ISSN 0041-1337 
Wang-Rodriguez, J. & Rearden, A. (1995). Effect of crossmatching on outcome in organ 
transplantation. Critical Reviews in  Clinical and  Laboratory Science,Vol.32, No.4, 
(n.d.), pp.345-376. 
www.intechopen.com
 Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney Transplantation 53 
Warren, D.; Zachary, A. & Sonnenday, C. (2004). Successful renal transplantation across 
simultaneous ABO incompatible and positive crossmatch barriers. American Journal 
of Transplantation, Vol.4, No.4, (April 2004), pp.561-568, ISSN 1600-6135 
Watanabe, J. & Scornik, J. (2005). IVIG and HLA antibodies. Evidence for inhibition of 
complement activation but not for anti-idiotypic activity. American Journal of 
Transplantation, Vol.5, No.11, (n.d.), pp.2786-2790. 
Weinstein, R. (2003). Basic Principles of Therapeutic Blood Exchange. In: Apheresis: principles 
and practice, McLeod, B. & Weinstein, R., pp.295-320, AABB Press, ISBN 1563951703, 
Bethesda, MD 
Williams KA; Hart, D.N.; Fabre, J.W. 1980Distrinution and quantitation of HLA-ABC and 
DR (Ia) antigens on human kidney and other tissues. Transplantation, Vol.29, No. 4, 
(n.d.), pp.274-279. 
Winters, J. et al. (2004). Plasma exchange conditioning for ABO-incompatible renal 
transplantation. Journal of clinical apheresis, Vol.19, No.2, (April 2004), pp.79-85, 
ISSN 0733-2459 
Worthington, J. et al. (2003). Posttransplantation production of donor HLA-specific 
antibodies as a predictor of renal transplant outcome. Transplantation, Vol.75, No.7, 
(n.d.), pp.1034-1040, ISSN 0041-1337 
Yabu, J. et al. (2011). C1q-Fixing Human Leukocyte Antigen Antibodies Are Specific for 
Predicting Transplant Glomerulopathy and Late Graft Failure After Kidney 
Transplantation. Transplantation,  Vol.91, No.3, (February 2011), pp.342-347 
Yard, B. et al. (1993). The Clinical Significance of Allospecific Antibodies Against 
Endothelial Cells Detected with An Antibody Dependent Cellular Cytotoxicity 
Assay for Vascular Rejection and Graft Loss After Renal Transplantation. 
Transplantation, Vol.55, No.6, (June 1993), pp.1287-1293, ISSN 0041-1337 
Yoo, Z. et al.  (1995). Human IL-17 - A Novel Cytokine Derived from T-Cells. Journal of 
Immunology, Vol.155, No.12, (December 1995), pp.5483-5486. 
Yung, G. et al. (2007). Flow cytometric measurement of ABO antibodies in ABO-
incompatible living donor kidney transplantation. Transplantation, Vol.84, No.12, 
Suppl. 3, (n.d.), pp.20-31. 
Zachary, A. et al. (2003). Specific and durable elimination of antibody to donor HLA 
antigens in renal-transplant patients. Transplantation, Vol.76, No.10, (November 
2003), pp.1519-1525 
Zachary, A.; Montgomery, R. & Leffell, M. (2005). Factors associated with and predictive of 
persistence of donor-specific antibody after treatment with plasmapheresis and 
intravenous immunoglobulin. Human Immunology, Vol.66, No.4, (n.d.), pp.364-370. 
Zachary, A. et al. (2009).Naturally occurring interference in Luminex assays for HLA-
specific antibodies: characteristics and resolution. Human Immunology,  Vol.70, 
No.7, (April 2009) pp.496-501 
Zachary, A. et al. (2009). Using real data for a virtual crossmatch. Human Immunology, 
Vol.70, No.8, (n.d.), pp.574-579.Zeevi, A. et al. (2009). Emerging role of donor-
specific anti-human leukocyte antigen antibody determination for clinical 
management after solid organ transplantation. Human Immunology, Vol.70, No.8, 
(n.d.), pp.645-650. 
www.intechopen.com
 Kidney Transplantation – New Perspectives 54
Zemmour, J. & Parham, P. (1992). Distinctive Polymorphism at the HLA-C Locus - 
Implications for the Expression of HLA-C. Journal of  Experimental Medicine,Vol.176, 
No.4, (November 1992), pp.937-950, ISSN 0022-1007 
Zilow, G.; Kirschfink, M. & Roelcke, D. (1994). Red-Cell Destruction in Cold Agglutinin 
Disease. Infusiontherapy and Transfusionmedicine, Vol.21, No.6, (December 1994), 
pp.410-415, ISSN 1019-8466 
Zwirner, N. et al. (2006). Immunobiology of the human MHC class I chain-related gene A 
(MICA): from transplant immunology to tumor immune escape. Immunologia, 
Vol.25, No.1, (n.d.), pp.25-38. 
www.intechopen.com
Kidney Transplantation - New Perspectives
Edited by Dr Magdalena Trzcinska
ISBN 978-953-307-684-3
Hard cover, 334 pages
Publisher InTech
Published online 23, August, 2011
Published in print edition August, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Although many years have passed since the first successful kidney transplantation, the method, although no
longer considered a medical experiment, is still perceived as controversial and, as such, it triggers many
emotions and thatâ€™s why conscious educational efforts are still needed for kidney transplantation, for many
people being the only chance for an active lifestyle and improved quality of life, to win common social
acceptance and stop triggering negative connotations. Apart from transplantation controversies piling up over
years transplantologists also have to face many other medical difficulties. The chapters selected for this book
are of high level of content, and the fact that their authors come from many different countries, and sometimes
even cultures, has facilitated a comprehensive and interesting approach to the problem of kidney
transplantation. The authors cover a wide spectrum of transplant-related topics.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Andrew Lobashevsky (2011). Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney
Transplantation, Kidney Transplantation - New Perspectives, Dr Magdalena Trzcinska (Ed.), ISBN: 978-953-
307-684-3, InTech, Available from: http://www.intechopen.com/books/kidney-transplantation-new-
perspectives/characteristics-detection-and-clinical-relevance-of-alloantibodies-in-kidney-transplantation
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
